#  @ImmunityBio ImmunityBio, Inc. ImmunityBio, Inc. posts on X about future, in the, hope, we are the most. They currently have [---------] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours. ### Engagements: [-----] [#](/creator/twitter::1242955282872848384/interactions)  - [--] Week [------] +222% - [--] Month [-------] +328% - [--] Months [-------] +293% - [--] Year [-------] +367% ### Mentions: [--] [#](/creator/twitter::1242955282872848384/posts_active)  - [--] Week [--] +81% - [--] Month [--] +48% - [--] Months [--] +1.40% - [--] Year [---] +83% ### Followers: [---------] [#](/creator/twitter::1242955282872848384/followers)  - [--] Week [------] +1.50% - [--] Month [------] +17% - [--] Months [------] +55% - [--] Year [------] +426% ### CreatorRank: [-------] [#](/creator/twitter::1242955282872848384/influencer_rank)  ### Social Influence **Social category influence** [countries](/list/countries) [finance](/list/finance) [travel destinations](/list/travel-destinations) [ncaa football](/list/ncaa-football) [ncaa basketball](/list/ncaa-basketball) **Social topic influence** [future](/topic/future), [in the](/topic/in-the), [hope](/topic/hope), [we are](/topic/we-are), [science](/topic/science) #4764, [the first](/topic/the-first), [united states](/topic/united-states), [health](/topic/health), [$ibrx](/topic/$ibrx) #10, [approval](/topic/approval) **Top accounts mentioned or mentioned by** [@petitnong_](/creator/undefined) [@drpatrick](/creator/undefined) [@phoenxlights](/creator/undefined) [@jayosays](/creator/undefined) [@saiseiinvesting](/creator/undefined) [@bladdercancerus](/creator/undefined) [@urocancermd](/creator/undefined) [@drpatsoonshiong](/creator/undefined) [@oshin76](/creator/undefined) [@foreveruseless_](/creator/undefined) [@garyr9912](/creator/undefined) [@xrphomie](/creator/undefined) [@usfda](/creator/undefined) [@urologytimes](/creator/undefined) [@urologycarefdn](/creator/undefined) [@meeradnan89945](/creator/undefined) [@epboston](/creator/undefined) [@maschotta_adam](/creator/undefined) [@truedat999](/creator/undefined) [@amerurological](/creator/undefined) **Top assets mentioned** [ImmunityBio, Inc. Common Stock (IBRX)](/topic/$ibrx) ### Top Social Posts Top posts by engagements in the last [--] hours "ImmunityBio has reached many important milestones this year we owe that progress to our extended family of trial investigators & fellow scientists trial volunteers our partners & our dedicated employees. Wishing you & your families a joyous holiday season❤" [X Link](https://x.com/ImmunityBio/status/1606061039463944213) 2022-12-22T22:56Z [----] followers, [----] engagements "We're #Hiring: Clinical Research Associate Join our experienced mission-driven team thats working to give new hope and a better quality of life to millions of patients around the world. Visit our #Careers page to learn more: #BiotechJobs" [X Link](https://x.com/ImmunityBio/status/1695166681075577003) 2023-08-25T20:10Z [----] followers, [---] engagements "At ImmunityBio our goal is to engage & enhance the immune systems natural ability to fight even difficult-to-treat diseases creating better treatments for better outcomes. Learn more about our research and #clinicaltrials: #CancerVaccine #immunotherapy" [X Link](https://x.com/ImmunityBio/status/1696203009393410316) 2023-08-28T16:48Z [----] followers, [---] engagements "We're #Hiring: Senior Facilities Planner Join our experienced mission-driven team thats working to give new hope and a better quality of life to millions of patients around the world. Visit our #Careers page to learn more: #BiotechJobs" [X Link](https://x.com/ImmunityBio/status/1696999003106234580) 2023-08-30T21:31Z [----] followers, [---] engagements "We're #Hiring: Manager QCA Potency Assay and Trending Join our experienced mission-driven team thats working to give new hope and a better quality of life to millions of patients around the world. Visit our #Careers page to learn more: #BiotechJobs" [X Link](https://x.com/ImmunityBio/status/1700301513631932679) 2023-09-09T00:14Z [----] followers, [---] engagements "#LynchSyndrome increases the risk of various cancers for people living with it. That's why we're working w/ @theNCI on a clinical study using our investigational therapies to prevent related cancers. Learn more about the inherited condition: via @TODAYshow" [X Link](https://x.com/ImmunityBio/status/1704627987558109416) 2023-09-20T22:45Z [----] followers, [---] engagements "Last year researchers from @WUSTLmed published data in @ScienceTM on Natural Killer Cells. This data further demonstrates the potential use of memory-like NK cells plus N-803 for treating cancer: #CancerResearch #immunotherapy" [X Link](https://x.com/ImmunityBio/status/1714751460171296960) 2023-10-18T21:13Z [----] followers, [---] engagements "Today we announced that @US_FDA has accepted for review our BLA resubmission for N-803 plus BCG for BCG-unresponsive NMIBC. New PDUFA date is April [--] [----]. Full press release: $IBRX #NMIBC" [X Link](https://x.com/ImmunityBio/status/1717547401433510096) 2023-10-26T14:23Z [----] followers, [----] engagements "In Case You Missed It: Last week we had the opportunity to participate in the 35th Annual @Piper_Sandler Healthcare Conference. Watch a replay of the presentation here: $IBRX #immunotherapy #CancerResearch" [X Link](https://x.com/ImmunityBio/status/1732087690160415209) 2023-12-05T17:21Z [----] followers, [---] engagements "February 1st marks the beginning of #BlackHistoryMonth ImmunityBio celebrates the Black pioneers in medicine and recognizes their groundbreaking achievements for the Urology community. Visit this article created by #AUA and #UCF to learn more:" [X Link](https://x.com/ImmunityBio/status/1753095871388930344) 2024-02-01T16:40Z [----] followers, [---] engagements "Dive into the latest research and advancements in urology with us at #AUA24 Join ImmunityBio at the @AmerUrological annual meeting in San Antonio May 3-6. Find us at booth #1931. More info: #Urology #AUAMembers" [X Link](https://x.com/ImmunityBio/status/1762887412475207840) 2024-02-28T17:08Z [----] followers, [---] engagements "#ChapelHill @BCAN #Bladdercancer Walk: ImmunityBio is proud to co-sponsor the BCAN Walk to End Bladder Cancer. Thank you BCAN for the important work you do everyday on behalf of bladder cancer patients and their caregivers" [X Link](https://x.com/ImmunityBio/status/1784328508585742397) 2024-04-27T21:07Z [----] followers, [----] engagements "Join us at #AUA24 for a groundbreaking discussion on next-gen immunotherapy for bladder cancer with @UroCancerMD and @DrPatSoonShiong. Details: Friday. 5/3 @ 3:15 CDT in the Learning Lab at AUA Square. #NMIBC #Immunotherapy" [X Link](https://x.com/ImmunityBio/status/1785812194241761595) 2024-05-01T23:23Z [----] followers, [----] engagements "Attending #AUA24 Dive into the future of bladder cancer treatment with ImmunityBio founder @DrPatSoonShiong and @UroCancerMD. Learn how Anktiva revolutionizes therapy approaches tomorrow May [--] @ 3:15 CDT in the Learning Lab at AUA Square. #BladderCancer #Immunotherapy" [X Link](https://x.com/ImmunityBio/status/1786067972819448210) 2024-05-02T16:19Z [----] followers, [---] engagements "🚨On the heels of the FDA approval of our combination therapy for treatment of #NMIBC ImmunityBio and @seruminstindia have agreed to an exclusive arrangement for global supply of BCG. Read More: https://immunitybio.com/immunitybio-serum-institute-of-india-agree-on-an-exclusive-arrangement-for-global-supply-of-bacillus-calmette-guerin-bcg-across-all-cancer-types https://immunitybio.com/immunitybio-serum-institute-of-india-agree-on-an-exclusive-arrangement-for-global-supply-of-bacillus-calmette-guerin-bcg-across-all-cancer-types" [X Link](https://x.com/anyuser/status/1786140612422709427) 2024-05-02T21:08Z 16.5K followers, [----] engagements "Hear from @DrPatSoonShiong himself on the potential of Anktiva in battling bladder cancer alongside @UroCancerMD at #AUA24. Join them today @ 3:15 CDT at the Learning Lab at AUA Square for an illuminating discussion. #BladderCancer #NMIBC" [X Link](https://x.com/ImmunityBio/status/1786419184542326868) 2024-05-03T15:34Z [----] followers, [----] engagements "Don't miss out 3:15 CDT at the Learning Lab at AUA Square: @DrPatSoonShiong's in-depth conversation with @UroCancerMD on the potential of Anktiva in battling #BladderCancer. #AUA24 #NMIBC http://bit.ly/4ddHQEK http://bit.ly/4ddHQEK" [X Link](https://x.com/ImmunityBio/status/1786478087128969680) 2024-05-03T19:29Z [----] followers, [----] engagements "ICYMI: AUA Daily News covered @drpatrick 's fireside chat with Dr. Sam Chang @UroCancerMD at #AUA2024" [X Link](https://x.com/anyuser/status/1786912140961743266) 2024-05-05T00:13Z 16.5K followers, [----] engagements "ImmunityBios state-of-the-art GMP biological manufacturing facility in Dunkirk New York https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-completes-gmp-drug-substance-manufacturingfield_nir_news_date_valuemin= https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-completes-gmp-drug-substance-manufacturingfield_nir_news_date_valuemin=" [X Link](https://x.com/anyuser/status/1787859710944674280) 2024-05-07T14:59Z 16.5K followers, [----] engagements "We're pleased to announce we've completed GMP drug substance manufacturing sufficient for [------] doses of our newly approved treatment. Exciting times ahead https://shorturl.at/MOW08 https://shorturl.at/MOW08" [X Link](https://x.com/anyuser/status/1787897895993360693) 2024-05-07T17:30Z 16.5K followers, [----] engagements "ImmunityBio is at the forefront of transforming bladder cancer treatment. Our innovative research aims to develop more effective therapies. Visit us to learn about our groundbreaking work and how we're making a difference: #BladderCancer #ImmunityBio https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/" [X Link](https://x.com/anyuser/status/1788691675809718477) 2024-05-09T22:05Z 16.5K followers, [----] engagements "Did you know #BladderCancer is the 4th most commonly diagnosed cancer among veterans. #BladderCancerAwareness month is more than a hashtag it's a call to action for sharing vital info & honoring the resilience of those who've served our country. #MemorialDay @BladderCancerUS" [X Link](https://x.com/ImmunityBio/status/1795105462263631894) 2024-05-27T14:51Z [----] followers, [----] engagements "ImmunityBio founder @DrPatSoonShiong shared his remarkable journey on the #HealthcareUnfiltered podcast. From apartheid-era South Africa to global success he overcame adversity pioneered cancer treatments and continues to make a difference. Listen: https://tinyurl.com/5n8bm59n https://tinyurl.com/5n8bm59n" [X Link](https://x.com/ImmunityBio/status/1813222429785006125) 2024-07-16T14:41Z [----] followers, [----] engagements "If you are passionate about our mission to develop innovative therapies that target some of the most difficult-to-treat human diseases consider joining our expanding team of talented professionals. View our #OpenPositions here: https://immunitybio.com/careers/ https://immunitybio.com/careers/" [X Link](https://x.com/ImmunityBio/status/1815460239875129771) 2024-07-22T18:53Z [----] followers, [----] engagements "Our CTO Enrique Dilon Ph.D. recently spoke with @BioProcessOL @mattpillar about his role and the company-wide decisions that go into the transition from FDA approval to the commercialization of Anktiva. Listen here: #BusinessOfBiotech https://shorturl.at/Np9cw https://shorturl.at/Np9cw" [X Link](https://x.com/ImmunityBio/status/1815769237312708884) 2024-07-23T15:21Z [----] followers, [----] engagements "Today is #WorldLungCancerDay. At ImmunityBio were pioneering advanced immunotherapy treatments to bolster immune responses and improve outcomes. Together we can make a difference. Learn more: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/" [X Link](https://x.com/ImmunityBio/status/1819028547178320243) 2024-08-01T15:12Z [----] followers, [----] engagements "Today we announced that we are studying ANKTIVA in combination with the investigational AdHER2DC cancer vaccine as a potential treatment for endometrial cancer aiming to improve outcomes and sustain clinical response. Learn more: https://immunitybio.com/immunitybio-announces-study-of-anktiva-in-combination-with-the-adher2dc-cancer-vaccine-as-a-potential-therapy-to-control-endometrial-cancer https://immunitybio.com/immunitybio-announces-study-of-anktiva-in-combination-with-the-adher2dc-cancer-vaccine-as-a-potential-therapy-to-control-endometrial-cancer" [X Link](https://x.com/ImmunityBio/status/1820809392335544823) 2024-08-06T13:09Z [----] followers, [----] engagements "We look forward to attending the @BladderCancerUS Think Tank Program. As we continue to strive for advancements in bladder cancer therapies we are committed to pioneering new treatments that enhance patient outcomes. #BCANThinkTank" [X Link](https://x.com/ImmunityBio/status/1821196414510362978) 2024-08-07T14:47Z [----] followers, [----] engagements "According to @BladderCancerUS a firefighter's prolonged exposure to harmful chemicals increases their risk of being diagnosed with #BladderCancer. ImmunityBio recognizes the urgent need to prevent surgical removal of the bladder. Read more: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/" [X Link](https://x.com/ImmunityBio/status/1825541282397352140) 2024-08-19T14:32Z [----] followers, [----] engagements "Our research in oncology and infectious diseases aims to provide patients with hope for better outcomes and improved quality of life. Learn more about our approach: https://immunitybio.com/patients https://immunitybio.com/patients" [X Link](https://x.com/ImmunityBio/status/1826275454153871602) 2024-08-21T15:09Z [----] followers, [----] engagements "ImmunityBio's mission is to address unmet needs in #Oncology and #InfectiousDisease by leveraging the patient's own immune system to not only fight illness but offer long-term protection. Learn more: https://immunitybio.com/about/ https://immunitybio.com/about/" [X Link](https://x.com/ImmunityBio/status/1826991761916580225) 2024-08-23T14:35Z [----] followers, [----] engagements "The ImmunityBio team looks forward to joining researchers healthcare professionals and advocacy partners at the New England AUA Sectional. #BladderCancerResearch" [X Link](https://x.com/ImmunityBio/status/1831702363482288596) 2024-09-05T14:34Z [----] followers, [----] engagements "Despite #LungCancer being one of the most common cancers worldwide there are very few successful treatment options once the cancer spreads beyond the lungs. We strive make advancements in #NSCLC treatments. Learn more: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/" [X Link](https://x.com/ImmunityBio/status/1835675116136780226) 2024-09-16T13:40Z [----] followers, [----] engagements "Were studying ANKTIVA in combination with the current standard of care vs. standard of care as first-line treatment for patients with stage [--] or [--] non-small cell lung cancer (NSCLC). Learn more about our phase [--] trial: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/" [X Link](https://x.com/ImmunityBio/status/1844746006690173112) 2024-10-11T14:24Z [----] followers, [----] engagements "Were looking forward to participating in the Jefferies London Healthcare Conference [----] taking place November [----] and marking the 15th anniversary of the largest healthcare-dedicated conference in Europe. Learn more: #JefferiesHealthcare https://immunitybio.com/immunitybio-to-participate-in-the-jefferies-london-healthcare-conference-2/ https://immunitybio.com/immunitybio-to-participate-in-the-jefferies-london-healthcare-conference-2/" [X Link](https://x.com/ImmunityBio/status/1848355111828951510) 2024-10-21T13:26Z 11.5K followers, [----] engagements "As part of our patient recruitment efforts we are working with advocacy groups and community leaders to raise awareness of our trials in communities that have historically not been involved in clinical studies. Learn more: https://immunitybio.com/diversity-equity-and-inclusion/ https://immunitybio.com/diversity-equity-and-inclusion/" [X Link](https://x.com/ImmunityBio/status/1849109985759809739) 2024-10-23T15:25Z 11.5K followers, [----] engagements "ImmunityBio announced the first patients dosed in our Phase I clinical study of CAR-NK therapy for the treatment of relapsed B-Cell non-Hodgkins lymphoma. Learn more: https://immunitybio.com/first-patients-dosed-in-phase-1-clinical-study-of-immunitybios-car-nk-cell-therapy-for-the-treatment-of-relapsed-b-cell-non-hodgkin-lymphoma/ https://immunitybio.com/first-patients-dosed-in-phase-1-clinical-study-of-immunitybios-car-nk-cell-therapy-for-the-treatment-of-relapsed-b-cell-non-hodgkin-lymphoma/" [X Link](https://x.com/anyuser/status/1849458725548962191) 2024-10-24T14:31Z 16.5K followers, 30.7K engagements "We're grateful to join fellow urology experts at the 100th Annual Western Section AUA Meeting. It is collaboration that drives us to innovate therapies that enhance patient outcomes" [X Link](https://x.com/ImmunityBio/status/1851264070218838088) 2024-10-29T14:05Z 11.5K followers, [----] engagements "We recognize the veterans whose sacrifices extend beyond their service. The U.S. Department of Veteran's Affairs reports nearly [----] veterans are faced with a lung cancer diagnosis each year. Learn more about our clinical trial: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/" [X Link](https://x.com/ImmunityBio/status/1854182440446620063) 2024-11-06T15:21Z [----] followers, [----] engagements "NMIBC's high recurrence rate is associated with diminished quality of life significant financial burden and greater mortality risk. ImmunityBio understands the critical need for innovative treatment options. Learn more about our studies: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/" [X Link](https://x.com/ImmunityBio/status/1854977825293455830) 2024-11-08T20:02Z [----] followers, [---] engagements "ImmunityBio is working towards a future free from fear of cancer. By tapping into the power of the immune system we're innovating therapies that bring new hope to patients and their loved ones. View our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/" [X Link](https://x.com/anyuser/status/1856346772286677388) 2024-11-12T14:42Z 16.5K followers, [----] engagements "Immunotherapy is revolutionizing modern medicine and we're proud to be at the forefront of advancing treatment options for cancer. Discover more about our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/" [X Link](https://x.com/ImmunityBio/status/1859254880428335552) 2024-11-20T15:18Z [----] followers, [----] engagements "This Thanksgiving we're deeply grateful to our clinical trial participants investigators and dedicated employees. Your contributions drive life-saving innovations bringing hope to patients and families" [X Link](https://x.com/ImmunityBio/status/1862202739553341465) 2024-11-28T18:31Z [----] followers, [----] engagements "We're grateful to attend the 25th Annual @UroOnc Meeting where we will collaborate with leading voices in the bladder cancer space as we work toward transformative advances in treatment" [X Link](https://x.com/ImmunityBio/status/1864323711966269530) 2024-12-04T14:59Z [----] followers, [----] engagements "ImmunityBio is proud to be at the forefront of cancer treatment innovation. Hear from CEO @richadcock as he discusses our novel FDA-approved immunotherapy for BCG-unresponsive NMIBC CIS and transformative investigational therapies for lung cancer and other difficult-to-treat diseases: https://www.onyxnewsroom.com/how-immunitybio-is-transforming-cancer-treatment-in-just-30-seconds-2/ https://www.onyxnewsroom.com/how-immunitybio-is-transforming-cancer-treatment-in-just-30-seconds-2/" [X Link](https://x.com/ImmunityBio/status/1864387774377271350) 2024-12-04T19:14Z [----] followers, [----] engagements "Each year in the U.S. over [------] people are diagnosed with lung cancer with the majority facing non-small cell lung cancer (NSCLC). Our N-803 investigational therapy is designed to enhance the activity of NK and T cells empowering the immune system to better combat NSCLC. Find out more about our approach: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/" [X Link](https://x.com/ImmunityBio/status/1866499590616125532) 2024-12-10T15:05Z [----] followers, [----] engagements "@UrologyTimes has named their top [--] videos of [----] including Dr. Patrick Soon-Shiong's interview on ANKTIVA as a treatment for non-muscle invasive bladder cancer carcinoma in situ. Watch here: https://www.urologytimes.com/view/dr-soon-shiong-discusses-the-fda-approval-of-n-803-in-nmibc https://www.urologytimes.com/view/dr-soon-shiong-discusses-the-fda-approval-of-n-803-in-nmibc" [X Link](https://x.com/ImmunityBio/status/1874226447365399003) 2024-12-31T22:49Z [----] followers, [---] engagements "Cancer is the leading cause of death among firefighters with studies showing they are 9% more likely to develop cancer and 14% more likely to die from cancer compared to the general population (National Institute for Occupational Safety and Health). At ImmunityBio we are dedicated to highlighting these risks and advancing outcomes for those impacted by cancer" [X Link](https://x.com/ImmunityBio/status/1877749507917746603) 2025-01-10T16:09Z [----] followers, [--] engagements "During Firefighter Cancer Awareness Month we recognize the unique health challenges firefighters face as a result of the job. Our commitment is to raise awareness about cancer risks and support those who dedicate their lives to our safety. Learn more by visiting the @BladderCancerUS website: https://bcan.org/find-support/firefighters-and-bladder-cancer/ https://bcan.org/find-support/firefighters-and-bladder-cancer/" [X Link](https://x.com/ImmunityBio/status/1878837791607369751) 2025-01-13T16:13Z [----] followers, [---] engagements "With the introduction of a permanent J-code (J9028) for ANKTIVA the billing and reimbursement process is now more efficient for healthcare providers. Learn more: https://immunitybio.com/immunitybio-announces-permanent-j-code-j9028-for-anktiva-is-now-effective/ https://immunitybio.com/immunitybio-announces-permanent-j-code-j9028-for-anktiva-is-now-effective/" [X Link](https://x.com/ImmunityBio/status/1879567091503858158) 2025-01-15T16:31Z [----] followers, [----] engagements "ImmunityBio is advancing our clinical development pipeline to address critical gaps in non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC) treatments with ANKTIVA. Read more: https://immunitybio.com/immunitybio-provides-regulatory-update-on-anticipated-fda-submissions-in-2025-following-meeting-with-the-agency/ https://immunitybio.com/immunitybio-provides-regulatory-update-on-anticipated-fda-submissions-in-2025-following-meeting-with-the-agency/" [X Link](https://x.com/ImmunityBio/status/1879906249757823475) 2025-01-16T14:59Z [----] followers, [--] engagements "ImmunityBio has announced our submission of marketing authorization applications for ANKTIVA to the European Union (EU) European Medicines Agency and the United Kingdoms (UK) Medicines and Healthcare products Regulatory Agency (MHRA). Learn more: https://immunitybio.com/immunitybio-provides-regulatory-update-on-global-submission-for-anktiva-bcg-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer-with-carcinoma-in-situ-in-europe-and-united-kingdom/" [X Link](https://x.com/ImmunityBio/status/1879906540859318511) 2025-01-16T15:00Z [----] followers, [----] engagements "Firefighters: Your health matters. This brave occupation comes with an increased risk of cancer including bladder cancer. Early detection is crucial to improving outcomes; if you're experiencing symptoms like blood in urine frequent urination or pain while urinating talk to your doctor about screening" [X Link](https://x.com/ImmunityBio/status/1880273318835548660) 2025-01-17T15:17Z [----] followers, [--] engagements "The battle against occupational cancer in firefighters starts with awareness and ends with action. Firefighters confront a higher risk of developing bladder cancer and ImmunityBio is committed to advancing treatments that improve outcomes for all affected. Read more about our research: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/" [X Link](https://x.com/ImmunityBio/status/1882082321370653082) 2025-01-22T15:06Z [----] followers, [---] engagements "Prolonged exposure to heat toxic smoke and the byproducts of fire have been shown to cause firefighters health issues like cancer heart disease respiratory diseases and more. We aim to shed light on the prevalence of these health risks the firefighter community faces to promote early screening and better outcomes" [X Link](https://x.com/ImmunityBio/status/1882814638783361059) 2025-01-24T15:36Z [----] followers, [----] engagements "ImmunityBio has announced the European Medicine Agencys acceptance of its marketing authorization application for ANKTIVA (in combination with BCG) to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. The application is based on promising results from the QUILT [-----] study marking a significant step forward in offering innovative treatment options to patients worldwide. Learn more: https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-european-medicines-agency-acceptancefield_nir_news_date_valuemin=" [X Link](https://x.com/ImmunityBio/status/1883899365171122551) 2025-01-27T15:26Z [----] followers, [----] engagements "The dangers of firefighting don't disappear when the gear comes off. Firefighters face increased risk of developing cancers including bladder cancer due to prolonged exposure to hazardous chemicals on the job. At ImmunityBio we are committed to advancing innovative treatments and improving outcomes for those affected by bladder cancer. Learn more about our efforts to bring hope and better outcomes to firefighters and all those impacted by bladder cancer: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/" [X Link](https://x.com/ImmunityBio/status/1884280596618158540) 2025-01-28T16:41Z [----] followers, [----] engagements "Immunityio has partnered with BeiGene (soon to be BeOne Medicines) for a Phase [--] trial aimed at evaluating the efficacy and safety of two immunotherapeutic agents in patients with metastatic non-small cell lung cancer (NSCLC) resistant to immune checkpoint inhibitors. Learn more about this effort to advance treatments for those facing unmet needs in oncology: https://immunitybio.com/immunitybio-announces-collaboration-with-beigene-on-confirmatory-phase-3-trial-of-anktiva-and-pd-1-checkpoint-inhibitor-combination-in-non-small-cell-lung-cancer/" [X Link](https://x.com/anyuser/status/1884598351653425546) 2025-01-29T13:43Z 16.5K followers, [----] engagements "As National Firefighter Cancer Awareness Month comes to a close ImmunityBio extends our heartfelt gratitude to the brave men and women who serve as firefighters. Your courage strength and unwavering commitment inspire us every day. We recognize the unique risks you face including the increased vulnerability to cancers like bladder cancer. That is why we remain steadfast in our mission to improve outcomes for those impacted by this disease. Thank you for protecting our communities" [X Link](https://x.com/ImmunityBio/status/1885344474819420532) 2025-01-31T15:08Z [----] followers, [----] engagements "At ImmunityBio we're focused on transforming the treatment landscape for non-small cell lung cancer with innovative therapies. Explore our approach and learn more: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/" [X Link](https://x.com/ImmunityBio/status/1887516130874696287) 2025-02-06T14:58Z [----] followers, [----] engagements "Bladder cancer awareness and education are critical especially for high-risk communities like firefighters. ImmunityBio is proud to sponsor this special edition of UrologyHealth Extra @UrologyCareFdn providing valuable insights and resources for those impacted by bladder cancer. Read more here: https://www.urologyhealth.org/healthy-living/urologyhealth-extra https://www.urologyhealth.org/healthy-living/urologyhealth-extra" [X Link](https://x.com/ImmunityBio/status/1889101656757031400) 2025-02-10T23:58Z [----] followers, 16.2K engagements "Are you looking to help shape the future of cancer treatment ImmunityBio is hiring passionate individuals committed to advancing research and developing innovative therapies. Start your journey with us: https://immunitybio.com/careers/ https://immunitybio.com/careers/" [X Link](https://x.com/ImmunityBio/status/1889322786902233371) 2025-02-11T14:37Z [----] followers, [----] engagements "Advancing cancer research means addressing inherited cancer-causing conditions like Lynch syndrome. ImmunityBio is conducting a clinical trial to explore innovative therapies for those diagnosed with Lynch syndrome. Learn more: https://immunitybio.com/lynch-syndrome/ https://immunitybio.com/lynch-syndrome/" [X Link](https://x.com/ImmunityBio/status/1890053039530328438) 2025-02-13T14:58Z [----] followers, [----] engagements "ImmunityBio announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has validated and accepted the marketing authorization application for ANKTIVA. The agency will now assess ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with bacillus Calmette-Gurin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Learn more:" [X Link](https://x.com/ImmunityBio/status/1890138134714937695) 2025-02-13T20:37Z [----] followers, [----] engagements "Through cutting-edge science and a patient-focused approach ImmunityBio is working to change the future of bladder cancer treatment. See how we're driving progress and delivering new hope to patients: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/" [X Link](https://x.com/ImmunityBio/status/1891869852849029312) 2025-02-18T15:18Z [----] followers, [----] engagements "ImmunityBio today announced that the FDA has authorized an Expanded Access Program (EAP) to improve U.S. patient access to BCG a standard-of-care treatment for non-muscle invasive bladder cancer. Learn more: https://immunitybio.com/fda-authorizes-immunitybio-to-provide-recombinant-bcg-rbcg-to-urologists-to-address-tice-bcg-shortage/ https://immunitybio.com/fda-authorizes-immunitybio-to-provide-recombinant-bcg-rbcg-to-urologists-to-address-tice-bcg-shortage/" [X Link](https://x.com/anyuser/status/1892214746734346424) 2025-02-19T14:08Z 16.5K followers, 25.3K engagements "Today we recognize the caregivers who provide support and compassion to patients facing cancer and serious illnesses. Your dedication is invaluable; we thank you for your commitment to those in need" [X Link](https://x.com/ImmunityBio/status/1892969731356831761) 2025-02-21T16:08Z [----] followers, [----] engagements "The FDA has granted ImmunityBio a Regenerative Medicine Advanced Therapy designation to evaluate whether ANKTIVA and CAR-NK can reverse lymphopenia in patients undergoing standard-of-care chemotherapy for locally advanced or metastatic pancreatic cancer. Learn more about our innovative approach to addressing this unmet need in cancer: https://immunitybio.com/immunitybio-receives-fda-rmat-designation-for-anktiva-and-car-nk-for-the-reversal-of-lymphopenia-in-patients-receiving-standard-of-care-chemotherapy-radiotherapy-and-in-treatment-of-multiply-rel/" [X Link](https://x.com/anyuser/status/1895267871821046081) 2025-02-28T00:20Z 16.5K followers, [----] engagements "Colorectal cancer is one of the most common cancers diagnosed in the U.S. and for some the risk is inherited. Up to 3% of all colorectal cancer cases are linked to Lynch syndrome yet many remain unaware of their genetic risk. Identifying Lynch syndrome early on can lead to potentially life-saving interventions. Learn more about the connection between Lynch syndrome and cancer risk: https://immunitybio.com/lynch-syndrome/ https://immunitybio.com/lynch-syndrome/" [X Link](https://x.com/ImmunityBio/status/1896588788560003514) 2025-03-03T15:49Z [----] followers, [----] engagements "Broadening treatment options is critical to advancing care for those affected by complex diseases like non-small cell lung cancer. With each advancement we move closer to more effective personalized approaches that address the unique challenges of these conditions. By focusing on innovation ImmunityBio aims to offer more hope for the patients who need it most. Learn more: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/" [X Link](https://x.com/ImmunityBio/status/1897366954400473307) 2025-03-05T19:21Z [----] followers, [----] engagements "Colorectal cancer remains a leading cancer in the U.S. with over [------] diagnosed each year. Lynch syndrome an inherited condition increases the risk of developing colorectal and other cancers. ImmunityBio is working to develop investigational immunotherapy products aimed at treating and preventing cancers associated with Lynch syndrome. Read more: https://immunitybio.com/lynch-syndrome/ https://immunitybio.com/lynch-syndrome/" [X Link](https://x.com/ImmunityBio/status/1899459725164732585) 2025-03-11T13:57Z [----] followers, [----] engagements "Today we announced our first patient dosed in our recombinant BCG (rBCG) FDA-authorized Expanded Access Program. With [--] sites launching providers like U.S. Urology Partners are helping address the nationwide BCG shortage. Learn more: https://immunitybio.com/immunitybio-announces-first-dosing-of-recombinant-bcg-rbcg-in-the-u-s-and-60-sites-in-the-process-of-launching/ https://immunitybio.com/immunitybio-announces-first-dosing-of-recombinant-bcg-rbcg-in-the-u-s-and-60-sites-in-the-process-of-launching/" [X Link](https://x.com/anyuser/status/1900184441634652624) 2025-03-13T13:57Z 16.5K followers, [----] engagements "ImmunityBio is dedicated to transforming the way we fight cancer and infectious diseases by empowering the body's own immune system. Our mission is to not only treat illness but to provide lasting protection that gives patients hope for a healthier future. Learn more about our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/" [X Link](https://x.com/anyuser/status/1902002967445897371) 2025-03-18T14:23Z 16.5K followers, [----] engagements "ImmunityBio is honored to be recognized as one of @FastCompany's most innovative companies of [----]. Innovation is at the core of our mission as we work to develop cutting-edge therapies and create better outcomes for patients. We remain committed to transforming the future of medicine and delivering hope to those in need" [X Link](https://x.com/anyuser/status/1902356161422409889) 2025-03-19T13:47Z 16.5K followers, [----] engagements "Lynch syndrome is the most common inherited cause of colorectal cancer and increases the risk of several other cancer types. At ImmunityBio were committed to advancing research that may offer new hope for individuals with Lynch syndrome including ongoing studies exploring the role of immunotherapy in this high-risk population" [X Link](https://x.com/ImmunityBio/status/1903564143564869873) 2025-03-22T21:47Z [----] followers, [--] engagements "At ImmunityBio our people are the driving force behind everything we do - advancing science supporting clinical research and working towards better treatment options for patients. If you're passionate about making a meaningful difference apply for one of our open positions today: https://immunitybio.com/careers/ https://immunitybio.com/careers/" [X Link](https://x.com/ImmunityBio/status/1904204739220484541) 2025-03-24T16:12Z [----] followers, [----] engagements "Bladder cancer can often go undetected until it has progressed. Early diagnosis and access to new treatment options are critical to improving outcomes for those affected. Learn more about how we're committed to advancing research and exploring new possibilities through our clinical trials: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/" [X Link](https://x.com/anyuser/status/1905255574281007352) 2025-03-27T13:48Z 16.5K followers, [----] engagements "Many individuals with Lynch syndrome are unaware that they carry the gene mutation until they're diagnosed with cancer making education early detection and clinical research critically important. Our clinical trial is designed to explore potential treatment options for those with Lynch syndrome. Learn more: https://immunitybio.com/lynch-syndrome/ https://immunitybio.com/lynch-syndrome/" [X Link](https://x.com/anyuser/status/1906706692777415126) 2025-03-31T13:54Z 16.5K followers, [----] engagements "We position ourselves at the forefront of cancer research striving to gain deeper insights and develop more effective treatments for patients. Learn more about our ongoing clinical trials: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/" [X Link](https://x.com/anyuser/status/1907488101699915970) 2025-04-02T17:39Z 16.5K followers, [----] engagements "Field Medical Director Dr. Rachel Elward reflects on the unique fulfillment of working in immunotherapy driven by the potential to transform patient lives. Learn more about our approach: https://immunitybio.com/patients/ https://immunitybio.com/patients/" [X Link](https://x.com/anyuser/status/1909624980712882466) 2025-04-08T15:10Z 16.5K followers, [----] engagements "ImmunityBios latest QUILT [-----] data demonstrates the longest duration of complete response and the highest rate of cystectomy avoidance within the non-muscle invasive bladder cancer space. Watch Dr. Sam Chang's oral presentation here: and explore the most recent data: https://immunitybio.com/unmatched-long-term-bladder-preservation-for-36-months-in-over-80-percent-of-responders-with-anktiva-plus-bcg-in-bcg-unresponsive-nmibc-cis-and-papillary-disease-alone-best-in-disease/ https://vimeo.com/1079187906utm_source=email&utm_medium=vimeo-email&utm_campaign=44349" [X Link](https://x.com/anyuser/status/1916842737867145398) 2025-04-28T13:11Z 16.5K followers, [----] engagements "During Bladder Cancer Awareness Month we at ImmunityBio reflect on our mission to innovate and improve the lives of those battling this disease. Our relentless pursuit of groundbreaking therapies underscores our commitment to delivering hope and better solutions for patients. Learn more by visiting https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/" [X Link](https://x.com/anyuser/status/1917991649663455447) 2025-05-01T17:16Z 16.5K followers, [----] engagements "We're focused on driving innovation in bladder cancer care - starting where it's most commonly diagnosed: non-muscle invasive disease. At ImmunityBio advancing treatment options remains a critical priority. Learn more: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/" [X Link](https://x.com/anyuser/status/1920136524362022924) 2025-05-07T15:19Z 16.5K followers, [----] engagements "We announced the signing of a strategic Memorandum of Understanding (MOU) to introduce the FDA-approved Cancer BioShield platform to Saudi Arabia and the broader Middle East. Learn more: https://immunitybio.com/immunitybio-saudi-arabias-ministry-of-investment-kfshrc-and-kaimrc-sign-strategic-memorandum-of-understanding-to-launch-cancer-bioshieldtm-platform-in-the-middle-east/ https://immunitybio.com/immunitybio-saudi-arabias-ministry-of-investment-kfshrc-and-kaimrc-sign-strategic-memorandum-of-understanding-to-launch-cancer-bioshieldtm-platform-in-the-middle-east/" [X Link](https://x.com/anyuser/status/1927365940112433441) 2025-05-27T14:07Z 16.5K followers, 10.6K engagements "Advanced ovarian cancer presents significant challenges especially for this with platinum-resistant recurrence. ImmunityBio is working on potential solutions through our clinical trial for recurrent platinum-resistant high-grade ovarian cancer. Our goal is to provide new hope where options are limited. Visit our website to learn more: https://immunitybio.com/ovarian-cancer/ https://immunitybio.com/ovarian-cancer/" [X Link](https://x.com/anyuser/status/1932476140897386578) 2025-06-10T16:33Z 16.5K followers, [----] engagements "At ImmunityBio our commitment to innovation drives us to explore new frontiers in medicine. From addressing genetic disorders like Lynch syndrome to tackling complex cancers such as bladder cancer we are dedicated to making a meaningful impact. Join us in our journey to transform the future of healthcare by viewing our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/" [X Link](https://x.com/anyuser/status/1933532401051054441) 2025-06-13T14:30Z 16.5K followers, [----] engagements "Annually over [------] people in the United States are diagnosed with lung cancer with the majority facing non-small cell lung cancer (NSCLC). We're working to enhance the activity of NK and T cells empowering the immune system to better combat NSCLC. Learn more about our approach: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/" [X Link](https://x.com/anyuser/status/1935701854182351180) 2025-06-19T14:11Z 16.5K followers, [----] engagements "The team at ImmunityBio extends our congratulations to Dr. Mary E. Brunkow Dr. Fred Ramsdell and Dr. Shimon Sakaguchi recipients of the [----] Nobel Prize in Physiology or Medicine. This groundbreaking research on regulatory T cells has advanced the scientific understanding of immune tolerance providing the foundation for developing novel therapies targeting cancer and infectious diseases. We recognize and applaud their contributions to immunology which continue to inspire innovation. Read more: https://www.nobelprize.org/prizes/medicine/2025/press-release/" [X Link](https://x.com/anyuser/status/1975933479604154618) 2025-10-08T14:37Z 16.5K followers, [----] engagements "Today we were able to participate in an insightful discussion organized by the Consulate of Denmark (@ICDK_CPH) about innovative ways industry & hospitals are collaborating on #clinicalresearch. We so appreciate the opportunity to take part in these important conversations. #icdk" [X Link](https://x.com/ImmunityBio/status/1616582728886910976) 2023-01-20T23:45Z 14.7K followers, [---] engagements "We are dedicated to conducting inclusive medical research through clinical trials aiming to advance treatments that can benefit all patients in need. Learn more about our efforts: https://immunitybio.com/diversity-equity-and-inclusion/ https://immunitybio.com/diversity-equity-and-inclusion/" [X Link](https://x.com/ImmunityBio/status/1894427535037141504) 2025-02-25T16:41Z [----] followers, [----] engagements "Lymphopenia is a serious condition affecting many patients with cancer - especially those undergoing chemotherapy or radiation. It can leave the immune system compromised and limit the body's ability to fight illness. We're working to address this challenge through our science and ongoing clinical research with a goal of improving outcomes by enhancing immune recovery. https://twitter.com/i/web/status/1937512789037449583 https://twitter.com/i/web/status/1937512789037449583" [X Link](https://x.com/anyuser/status/1937512789037449583) 2025-06-24T14:07Z 16.5K followers, [----] engagements "Join us in transforming the future of cancer treatment. ImmunityBio is advancing innovative therapies that bring new hope to patients facing some of the most challenging cancers. We're looking for passionate mission-driven individuals to grow with us. Be a part of something bigger. Explore open positions and apply today: https://immunitybio.com/careers/ https://immunitybio.com/careers/" [X Link](https://x.com/anyuser/status/1938252171390423075) 2025-06-26T15:05Z 16.5K followers, [----] engagements "Bladder cancer recurrence is a reality for nearly half of patients with non-muscle invasive disease. ImmunityBio is advancing immunotherapy-based research to help the body's own defenses recognize and fight cancer. Learn more: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/" [X Link](https://x.com/anyuser/status/1940406193060721095) 2025-07-02T13:44Z 16.5K followers, [----] engagements "On this Independence Day we recognize the sacrifices made for our freedom and the strength of the communities that continue to move our nation forward. The team at ImmunityBio wishes you a safe and happy holiday" [X Link](https://x.com/anyuser/status/1941182468197056957) 2025-07-04T17:09Z 16.5K followers, [----] engagements "Today we announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted the first marketing approval outside the United States for this novel lymphocyte-stimulating agent ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Gurin (BCG) for the treatment of certain bladder cancer patients. Learn more: https://immunitybio.com/uk-mhra-approves-immunitybios-anktiva-plus-bcg-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-carcinoma-in-situ/" [X Link](https://x.com/anyuser/status/1942403512689635618) 2025-07-08T02:01Z 16.5K followers, [----] engagements "Our scientists are working to develop remarkable new therapies that harness the body's inherent power by amplifying both the innate and adaptive branches of the immune system facilitating the attack and elimination of cancerous or infected cells today while building immunological memory for tomorrow. Learn more: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/" [X Link](https://x.com/anyuser/status/1943318052667576663) 2025-07-10T14:35Z 16.5K followers, [----] engagements "According to the American Cancer Society lung cancer accounts for nearly [--] in [--] cancer deaths in the United States. ImmunityBio is focused on developing therapies that address this ongoing health challenge. Read more: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/" [X Link](https://x.com/anyuser/status/1945128385400987918) 2025-07-15T14:28Z 16.5K followers, [----] engagements "Our scientists translate rigorous immunology research into innovative cell- and immune-based therapies working every day to expand treatment options and improve outcomes for patients" [X Link](https://x.com/anyuser/status/1947333307005554693) 2025-07-21T16:30Z 16.5K followers, [----] engagements "Weve reported a 60% revenue increase in Q2 [----] with year-to-date sales reaching $43M and a 246% growth in ANKTIVA sales since J-code issuance. Regulatory milestones continue to help us advance our mission of improving outcomes for patients. Read more: https://immunitybio.com/immunitybio-reports-60-increase-in-revenue-in-q2-2025-with-year-to-date-sales-of-43-million-and-246-unit-growth-since-j-code-with-regulatory-updates/ https://immunitybio.com/immunitybio-reports-60-increase-in-revenue-in-q2-2025-with-year-to-date-sales-of-43-million-and-246-unit-growth-since-j-code-with-regulatory-updates/" [X Link](https://x.com/anyuser/status/1948779388235120803) 2025-07-25T16:16Z 16.5K followers, [----] engagements "Lymphopenia remains a critical challenge for patients undergoing cancer treatment often compromising immune function and increasing the risk of complications. At ImmunityBio we are advancing clinical research aimed at promoting immune system recover and improving long-term outcomes for patients. Learn more: https://immunitybio.com/lymphopenia/ https://immunitybio.com/lymphopenia/" [X Link](https://x.com/anyuser/status/1950279918555975787) 2025-07-29T19:39Z 16.5K followers, [----] engagements "Last night on Killing Cancer our Founder and Executive Chairman @DrPatSoonShiong joined @ChrisCuomo to discuss why re-examining long-held assumptions about cancer is essential to advancing patients treatment options. The special underscores his decades-long commitment to pursuing better ways to treat cancer and improve outcomes work that ImmunityBio continues to drive forward every day. https://www.newsnationnow.com/health/newsnation-special-killing-cancer-treatment-soon-shiong/ https://www.newsnationnow.com/health/newsnation-special-killing-cancer-treatment-soon-shiong/" [X Link](https://x.com/ImmunityBio/status/1993687695457911206) 2025-11-26T14:26Z 15.5K followers, [----] engagements "Our founder and Executive Chairman Dr. Patrick Soon-Shiong had the honor of carrying the Olympic torch in Athens at the historic stadium - representing Los Angeles and the United States as the flame was passed to Italy for the [----] Games" [X Link](https://x.com/ImmunityBio/status/1996968135614730260) 2025-12-05T15:41Z 13.2K followers, [---] engagements "We've announced the Announce Inaugural U.S.-Saudi Biotech Alliance Summit which will bring together national leaders from the United States and the Kingdom of Saudi Arabia across government healthcare delivery biotechnology advanced manufacturing artificial intelligence and finance. The Summit is designed to foster implementation and collaboration to accelerate the development manufacturing and global deployment of next-generation immunotherapies and healthcare technologies. Learn more:" [X Link](https://x.com/ImmunityBio/status/2010728564639830078) 2026-01-12T15:00Z 13.8K followers, [----] engagements "Her Royal Highness Princess Dr. Haya Al Saud joined ImmunityBios Founder Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong for a discussion on the future of human health and resilience. As a leader of the Hevolution Foundation Princess Haya Al Saud shared a powerful vision for longevity science: emphasizing the importance of strengthening biology and expanding how progress is measured. My dream would be to make healthspan a measure of GDP. https://twitter.com/i/web/status/2011512082588631521 https://twitter.com/i/web/status/2011512082588631521" [X Link](https://x.com/ImmunityBio/status/2011512082588631521) 2026-01-14T18:53Z 16.5K followers, 77.8K engagements "Progress isn't measured only in milestones but in its impact on people. At ImmunityBio our work is centered on translating scientific innovation into outcomes that matter. Explore what's next in our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/" [X Link](https://x.com/ImmunityBio/status/2020898434296037673) 2026-02-09T16:31Z 16.5K followers, [----] engagements "Glioblastoma presents significant scientific and clinical challenges for patients and healthcare providers. The disease's limited treatment options emphasize the need for continued research and deeper scientific understanding. Our efforts in the glioblastoma space are focused on advancing studies designed to better comprehend the cancer and explore innovative therapeutic approaches. Learn more about ImmunityBio's glioblastoma clinical trial: https://immunitybio.com/glioblastoma/ https://immunitybio.com/glioblastoma/" [X Link](https://x.com/ImmunityBio/status/2021967726995181855) 2026-02-12T15:20Z 16.5K followers, 21.7K engagements "We believe our science has the potential to change the current paradigm of care for patients. Through a combination of highly experienced and talented people deep scientific knowledge and advanced research and manufacturing facilities ImmunityBio aims to improve outcomes for those living with difficult-to-treat diseases. Learn more about our founder's vision: https://immunitybio.com/founders-vision/ https://immunitybio.com/founders-vision/" [X Link](https://x.com/anyuser/status/1952429339519435237) 2025-08-04T18:00Z 16.5K followers, [----] engagements "Bladder cancer incidence is rising but so are the options for patients facing this diagnosis. At ImmunityBio we are working to improve outcomes and reduce the burden of treatment for patients with non-muscle invasive bladder cancer. As the need grows so does our commitment to developing solutions designed to harness the body's own immune system. https://twitter.com/i/web/status/1953111107784327668 https://twitter.com/i/web/status/1953111107784327668" [X Link](https://x.com/anyuser/status/1953111107784327668) 2025-08-06T15:09Z 16.5K followers, [----] engagements "Veterans are at an increased risk for bladder cancer due to exposure to carcinogens during service. Houston's Michael E. DeBakey VA Medical Center is now among the first VA hospitals to offer ANKTIVA for eligible veterans with BCG-unresponsive NMIBC. Read more: https://immunitybio.com/immunitybio-announces-houstons-michael-e-debakey-va-medical-center-is-among-the-first-va-hospitals-to-administer-anktiva-to-bladder-cancer-patients/" [X Link](https://x.com/anyuser/status/1954909747788058839) 2025-08-11T14:16Z 16.5K followers, [----] engagements "Our robust pipeline of clinical trials is all about turning insights into better outcomes for people facing a wide range of cancers. The ImmunityBio team remains committed to transforming research into tangible impact in the lives of patients. Explore our latest trials: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/" [X Link](https://x.com/anyuser/status/1955297290224378015) 2025-08-12T15:56Z 16.5K followers, [----] engagements "We announced early results from our QUILT-106 Phase I trial showing complete responses in the first two late-stage Non-Hodgkin Waldenstrm lymphoma patients treated with our CD19 CAR-NK cell therapy. Learn more: https://immunitybio.com/immunitybio-reports-complete-responses-in-non-hodgkin-waldenstrom-lymphoma-patients-with-chemotherapy-free-first-in-class-cd19-car-nk-immunotherapy/ https://immunitybio.com/immunitybio-reports-complete-responses-in-non-hodgkin-waldenstrom-lymphoma-patients-with-chemotherapy-free-first-in-class-cd19-car-nk-immunotherapy/" [X Link](https://x.com/anyuser/status/1955618969018388527) 2025-08-13T13:14Z 16.5K followers, 96.5K engagements "We're focused on innovating beyond standard treatments so that we can give the body the tools it needs to lead its own fight against cancer. Learn more about our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/" [X Link](https://x.com/anyuser/status/1962884518085546219) 2025-09-02T14:25Z 16.5K followers, [----] engagements "September marks Ovarian Cancer Awareness Month; a time to highlight the importance of early detection and ongoing research in the fight against this disease. Our team is always striving to push the boundaries of what is possible in ovarian cancer treatment. This month and every month we're dedicated to supporting patients and driving research forward. Learn more about our trial: https://immunitybio.com/ovarian-cancer/ https://immunitybio.com/ovarian-cancer/" [X Link](https://x.com/anyuser/status/1963336370929504515) 2025-09-03T20:20Z 16.5K followers, [----] engagements "With high rates of recurrence and the risk of advancing disease non-muscle invasive bladder cancer (NMIBC) remains a significant burden for both patients and healthcare providers. ImmunityBio is working to meet this challenge through the development of innovative treatment approached aimed at addressing the disease more effectively. Learn more: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/" [X Link](https://x.com/ImmunityBio/status/1967980297259213169) 2025-09-16T15:54Z 16.4K followers, [----] engagements "Lung cancer remains one of the leading causes of cancer-related deaths worldwide. At ImmunityBio we are advancing clinical research to explore new treatment options that harness the immune system. Our goal is to help expand possibilities for patients facing this disease. Learn more about our research: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/" [X Link](https://x.com/ImmunityBio/status/1970920651419681051) 2025-09-24T18:37Z 16.4K followers, [----] engagements "ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patients immune system not weakening it. View our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/" [X Link](https://x.com/ImmunityBio/status/1975225789219242102) 2025-10-06T15:45Z 16.4K followers, [----] engagements "Addressing the complexities of cancer and infectious diseases fuels our pursuit of new therapies that provide better outcomes for patients. If you're looking for a career with purpose become a part of our innovative team: https://immunitybio.com/careers/ https://immunitybio.com/careers/" [X Link](https://x.com/anyuser/status/1978108538200240587) 2025-10-14T14:40Z 16.5K followers, [----] engagements "This weekend's BCAN Patient Summit in Columbus brought together patients caregivers and healthcare professionals united in their commitment to improving outcomes and quality of life for those affected by bladder cancer. We're proud to stand alongside @BladderCancerUS and the broader advocacy community in this mission. https://twitter.com/i/web/status/1980289869403533722 https://twitter.com/i/web/status/1980289869403533722" [X Link](https://x.com/anyuser/status/1980289869403533722) 2025-10-20T15:07Z 16.5K followers, [----] engagements "At ImmunityBio we're dedicated to pushing the boundaries of medical research. By participating in our clinical trials individuals help us innovate and shape the future of cancer and infectious disease treatment. Learn more: https://immunitybio.com/find-a-trial/ https://immunitybio.com/find-a-trial/" [X Link](https://x.com/ImmunityBio/status/1982830206407831709) 2025-10-27T15:22Z 16.4K followers, [----] engagements "This National Urology Nurses Week ImmunityBio recognizes the dedication and expertise of urology nurses who provide compassionate care to patients every day. Your commitment helps improve outcomes and quality of life for individuals navigating urologic conditions including bladder cancer. Thank you for all that you do. https://twitter.com/i/web/status/1985360359205794185 https://twitter.com/i/web/status/1985360359205794185" [X Link](https://x.com/anyuser/status/1985360359205794185) 2025-11-03T14:56Z 16.5K followers, [----] engagements "Bladder Health Month provides us with an opportunity to reflect on the progress made through science and the compassion that drives it forward. Behind every clinical advancement are patients nurses physicians and caretakers determined to improve the future of bladder cancer care. We share that mission - to transform how bladder cancer is treated and to restore the body's ability to fight disease. Together with organizations like @BladderCancerUS and @UrologyCareFdn we work toward a future defined by better outcomes and renewed hope. https://twitter.com/i/web/status/1986084840928924003" [X Link](https://x.com/anyuser/status/1986084840928924003) 2025-11-05T14:55Z 16.5K followers, [----] engagements "We reported another quarter of strong results driven by increased demand for ANKTIVA and continued progress across our immunotherapy pipeline. In Q3 [----] we achieved significant year-to-date unit growth of 467% and $75 million in total product sales reflecting growing adoption in BCG-unresponsive non-muscle invasive bladder cancer. As we close out the year we remain committed to expanding access to our therapies advancing ongoing trials across multiple indications and executing our long-term vision to transform how cancer is treated. Read the full release including important cautionary" [X Link](https://x.com/anyuser/status/1986499820576801050) 2025-11-06T18:23Z 16.5K followers, [----] engagements "Every November Lung Cancer Awareness Month shines a light on the importance of education early detection and innovation. ImmunityBio is proud to support this awareness by pursuing scientific advancements designed to improve outcomes for patients facing lung cancer. Learn more: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/" [X Link](https://x.com/anyuser/status/1986810468066103519) 2025-11-07T14:58Z 16.5K followers, [----] engagements "Hope moves science forward. This month we honor the strength of the bladder cancer community and remain committed to transforming the treatment landscape through therapies that empower the immune system to fight cancer more effectively" [X Link](https://x.com/anyuser/status/1987906604298305898) 2025-11-10T15:34Z 16.5K followers, [----] engagements "This Veterans Day we reflect on the sacrifices made by those who served our country and the importance of improving health outcomes for veterans living with cancer and other serious diseases. Their resilience drives our ongoing pursuit of better care for all patients. Thank you. https://twitter.com/i/web/status/1988256773657292939 https://twitter.com/i/web/status/1988256773657292939" [X Link](https://x.com/anyuser/status/1988256773657292939) 2025-11-11T14:45Z 16.5K followers, [----] engagements "A recent Harris survey found that a vast majority of patients with non-muscle invasive bladder cancer (NMIBC) see intravesical chemotherapy as a last resort whereas 72% of immunotherapy recipients are satisfied with the duration of positive treatment effects. With patients at the forefront ImmunityBio continues to focus on innovative approaches designed to preserve bladder function and improve quality of life for those facing difficult treatment decisions. Read more here: https://immunitybio.com/new-survey-reveals-non-muscle-invasive-bladder-cancer-patients-seek-more-care-conversations/" [X Link](https://x.com/ImmunityBio/status/1988973742022881295) 2025-11-13T14:14Z 16.4K followers, [----] engagements "During our National Sales Meeting we came together to align on our vision for the year ahead; one rooted in innovation collaboration and meaningful impact. From inspiring presentations to strategy sessions every moment reinforced our dedication to driving progress for patients. We leave this meeting energized and focused on the work matters most - making a lasting difference in cancer care. https://twitter.com/i/web/status/1989382511408156911 https://twitter.com/i/web/status/1989382511408156911" [X Link](https://x.com/ImmunityBio/status/1989382511408156911) 2025-11-14T17:18Z 16.4K followers, [----] engagements "Lung Cancer Awareness Month is a time to recognize the progress made and the work still ahead. Non-small cell lung cancer (NSCLC) accounts for over 85% of all lung cancer cases in the U.S. with more than [------] diagnoses each year. Our work focuses on developing immunotherapy treatments that strengthen the body's natural immune response to target and destroy cancer cells. Through clinical research and collaboration we aim to deliver treatments that extend survival and improve quality of life for those affected. Learn more about our NSCLC clinical trial:" [X Link](https://x.com/ImmunityBio/status/1990464707497766949) 2025-11-17T16:59Z 16.4K followers, [----] engagements "We're honored to collaborate with the Saudi leadership team as we work to advance research and identify opportunities to reach more patients in need" [X Link](https://x.com/ImmunityBio/status/1991549552571326515) 2025-11-20T16:49Z 16.4K followers, 12.9K engagements "Our Founder and Executive Chairman Dr. Patrick Soon-Shiong recently sat down with @ChrisCuomo to share insights on the evolving landscape of cancer research and scientific innovation. Watch Killing Cancer Tuesday November [--] at 10p/9C on NewsNation" [X Link](https://x.com/ImmunityBio/status/1991600063983022232) 2025-11-20T20:10Z 16.4K followers, [----] engagements "The [----] National Health Interview Survey shows a powerful truth: if lung cancer screenings were to reach 100% [-----] lives could be saved in a mere five years. As we recognize Lung Cancer Awareness Month insights like this reinforce why ImmunityBio is investing in new approaches that aim to expand treatment options and address the challenges in lung cancer care. https://twitter.com/i/web/status/1991937478379626553 https://twitter.com/i/web/status/1991937478379626553" [X Link](https://x.com/ImmunityBio/status/1991937478379626553) 2025-11-21T18:31Z 16.4K followers, [----] engagements "As we reflect on this past year were reminded of the many things we hold with gratitude - our dedicated team the physicians and caregivers who make exceptional care possible and the patients whose resilience inspires every step forward. Together were continuing to advance science in the pursuit of better outcomes for those facing cancer. https://twitter.com/i/web/status/1994178833239691757 https://twitter.com/i/web/status/1994178833239691757" [X Link](https://x.com/ImmunityBio/status/1994178833239691757) 2025-11-27T22:57Z 16.4K followers, [----] engagements "While the exact cause of glioblastoma remains unknown several risk factors have been linked to increased risk - including age gender prior exposure to radiation and rare genetic conditions. For many patients however glioblastoma develops without a clear identifiable cause. At ImmunityBio we're conducting clinical research to better understand glioblastoma and evaluate investigational therapies that may offer new options for patients facing this difficult diagnosis. To learn more about our research visit https://immunitybio.com/glioblastoma/ https://immunitybio.com/glioblastoma/" [X Link](https://x.com/ImmunityBio/status/1995552883052609955) 2025-12-01T17:57Z 16.4K followers, [----] engagements "We look forward to participating in the Society of Urologic Oncology's 26th Annual Meeting. Opportunities for collaboration at these meetings are essential in advancing new breakthroughs in bladder cancer care and we're committed to contributing to ongoing innovation in the space. @UroOnc https://twitter.com/i/web/status/1995955710400791008 https://twitter.com/i/web/status/1995955710400791008" [X Link](https://x.com/ImmunityBio/status/1995955710400791008) 2025-12-02T20:38Z 16.4K followers, [----] engagements "Our Founder and Executive Chairman Dr. Patrick Soon-Shiong had the honor of carrying the Olympic torch in Athens at the historic stadium - representing Los Angeles and the United States as the flame was passed to Italy for the [----] Games" [X Link](https://x.com/ImmunityBio/status/1996968445309866245) 2025-12-05T15:42Z 16.4K followers, [----] engagements "Patient voices matter. According to a new Harris survey 72% of patients with non-muscle invasive bladder cancer express a preference to keep chemotherapy as a later option in their treatment plan instead of a first-line approach. At ImmunityBio we're working to develop patient-focused approaches that help the immune system target cancer cells. Read more: https://immunitybio.com/new-survey-reveals-non-muscle-invasive-bladder-cancer-patients-seek-more-care-conversations/ https://immunitybio.com/new-survey-reveals-non-muscle-invasive-bladder-cancer-patients-seek-more-care-conversations/" [X Link](https://x.com/ImmunityBio/status/1998409520234836134) 2025-12-09T15:08Z 16.4K followers, [----] engagements "Non-muscle invasive bladder cancer is challenging due to its tendency to recur often bringing financial strain and reduced quality of life for patients. At ImmunityBio we're dedicated to bringing forward new therapies that offer meaningful hope to those navigating this condition. Learn more about our efforts in the bladder cancer space: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/" [X Link](https://x.com/ImmunityBio/status/1999178598075498946) 2025-12-11T18:04Z 16.4K followers, [----] engagements "Lymphopenia can be a significant concern for patients with cancer as both chemotherapy and radiation can markedly lower lymphocyte levels. Reduced immune cell counts may affect how patients tolerate treatment and respond to infections. Learn more about how we're working to address lymphopenia for better patient outcomes: https://immunitybio.com/lymphopenia/ https://immunitybio.com/lymphopenia/" [X Link](https://x.com/ImmunityBio/status/2000581103527350491) 2025-12-15T14:57Z 16.4K followers, [----] engagements "New data from our Phase 2/3 study shows that ANKTIVA (nogapendekin alfa inbakicept) plus BCG demonstrated a 96% overall survival rate at three years in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer (NMIBC). These findings add to the clinical significance of immunotherapy's role in bladder cancer a space where treatment options have historically been limited. Read more:" [X Link](https://x.com/ImmunityBio/status/2000945223799877656) 2025-12-16T15:04Z 16.4K followers, 10.4K engagements "As we reflect on the year behind us we're grateful for the progress made through science collaboration and shared purpose. Without the patients caregivers healthcare heroes researchers and our amazing team this year's progress would not have been possible. At ImmunityBio our work continues with a clear focus: advancing therapies that support better patient outcomes. We wish you health and peace this holiday season. https://twitter.com/i/web/status/2004218295092686957 https://twitter.com/i/web/status/2004218295092686957" [X Link](https://x.com/ImmunityBio/status/2004218295092686957) 2025-12-25T15:50Z 16.4K followers, [----] engagements "ImmunityBio's Founder Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong has been recognized by @oncodaily as one of The [---] Most Influential People in Oncology in [----]. Dr. Soon-Shiong has earned this honor in recognition of his lifelong commitment to science medicine and patient care a commitment that inspires our team and our partners every day said Richard Adcock President and CEO of ImmunityBio. His ideas and leadership are a driving force powering our mission to bring transformative therapies to people living with cancer and other serious" [X Link](https://x.com/ImmunityBio/status/2005641948380668297) 2025-12-29T14:07Z 16.4K followers, [----] engagements "As we reflect on [----] we recognize a year shaped by collaboration scientific progress and meaningful engagement across the healthcare community. From connecting with patients and their caregivers to working cross-functionally as a means of moving initiatives forward each effort contributed to strengthening our mission and vision. Looking ahead to [----] we remain focused on building on this momentum; continuing to advance our science and support important communities with purpose and intention. Learn more about our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/" [X Link](https://x.com/ImmunityBio/status/2006804505493492147) 2026-01-01T19:07Z 16.4K followers, [----] engagements "Firefighters face a higher risk of bladder cancer and other cancers due to repeated exposure to carcinogens in the line of duty. While they dedicate their lives to protecting others their own health is often put at risk in the process. During Firefighter Cancer Awareness Month ImmunityBio remains focused on supporting efforts that increase awareness of cancer risk promote informed conversations between patients and healthcare providers and advance research aimed at improving outcomes for those affected by non-muscle invasive bladder cancer. https://twitter.com/i/web/status/2007102939631136897" [X Link](https://x.com/ImmunityBio/status/2007102939631136897) 2026-01-02T14:53Z 16.4K followers, [----] engagements "In [----] the International Agency for Research on Cancer (IARC) classified firefighting as a Class [--] carcinogenic occupation the highest level of evidence linking an exposure to cancer in humans. This designation reflects consistent documentation that firefighters encounter carcinogens through multiple pathways including: inhalation of toxic smoke dermal absorption of chemicals and contaminated turnout gear and equipment. These exposure have been associated with an increased risk of several cancers including bladder cancer. Understanding these exposure pathways is essential to advancing" [X Link](https://x.com/ImmunityBio/status/2008549875915608495) 2026-01-06T14:43Z 16.4K followers, [----] engagements "You can help shape the future of cancer treatment by joining the ImmunityBio team. We're hiring passionate individuals committed to advancing research and developing innovative therapies that improve patient outcomes. Start your journey with us: https://immunitybio.com/careers/ https://immunitybio.com/careers/" [X Link](https://x.com/ImmunityBio/status/2009660562444361784) 2026-01-09T16:16Z 16.4K followers, [----] engagements "We've announced the Inaugural U.S.-Saudi Biotech Alliance Summit which will bring together national leaders from the United States and the Kingdom of Saudi Arabia across government healthcare delivery biotechnology advanced manufacturing artificial intelligence and finance. The Summit is designed to foster implementation and collaboration to accelerate the development manufacturing and global deployment of next-generation immunotherapies and healthcare technologies. Learn more:" [X Link](https://x.com/ImmunityBio/status/2010782844382236948) 2026-01-12T18:36Z 16.4K followers, [----] engagements "Were continuing to advance our first-line BCG-nave non-muscle invasive bladder cancer program with enrollment exceeding expectations in our randomized registrational trial evaluating ANKTIVA plus BCG. These early milestones underscore our continued focus on moving this program forward and addressing unmet needs in bladder cancer. Read more: https://immunitybio.com/immunitybio-advances-first-line-bcg-naive-nmibc-program-with-enrollment-exceeding-expectations-and-positive-interim-analysis-for-anktiva-plus-bcg/" [X Link](https://x.com/ImmunityBio/status/2012186391854338209) 2026-01-16T15:33Z 16.4K followers, 10.1K engagements "Cancer is a leading cause of death among firefighters accounting for approximately 66% of firefighter line-of-duty deaths according to the Firefighter Cancer Support Network. These exposures have been linked to elevated cancer risk across multiple sites including bladder cancer. Our work is informed by the realities of occupational cancer risk and underscores the importance of continued research that focuses on improving outcomes for affected patients. Learn more about our efforts in the bladder cancer space: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/" [X Link](https://x.com/ImmunityBio/status/2013305111976493266) 2026-01-19T17:38Z 16.4K followers, [----] engagements "We've announced our new study called COVID-4.019-Long which further expands our clinical research efforts to assess ANKTIVAs potential beyond cancer or cancer-related diseases. Learn more about the study and its potential impact: https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-phase-2-study-anktivar-patients-long-covidfield_nir_news_date_valuemin= https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-phase-2-study-anktivar-patients-long-covidfield_nir_news_date_valuemin=" [X Link](https://x.com/anyuser/status/1957786038698668359) 2025-08-19T12:45Z 16.4K followers, 19.2K engagements "Weve announced that our initial data shows 100% disease control in [--] out of [--] patients with recurrent glioblastoma after being treated with our ANKTIVA NK cell therapy plus the Optune Gio device. Read more: https://immunitybio.com/initial-data-shows100-disease-control-in-5-out-of-5-patients-with-recurrent-glioblastoma-with-two-patients-in-near-complete-response-treated-with-immunitybios-anktiva-nk-cell-therapy-p/" [X Link](https://x.com/anyuser/status/1960322847512912375) 2025-08-26T12:46Z 16.5K followers, 37.6K engagements "Weve announced new paradigm-changing findings from the Phase [--] QUILT-3.055 study demonstrating ANKTIVA (nogapendekin alfa inbakicept-pmln) reverses lymphopenia (low natural killer and T cells) in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer (NSCLC) with this reversal resulting in significant prolonged median overall survival (mOS). Read more: https://immunitybio.com/immunitybios-anktiva-reverses-lymphopenia-and-extends-overall-survival-in-patients-with-advanced-non-small-cell-lung-cancer-resistant-to-checkpoint-therapy/" [X Link](https://x.com/anyuser/status/1965043802164654466) 2025-09-08T13:25Z 16.5K followers, 13.3K engagements "ANKTIVA plus BCG has received a positive recommendation for marketing authorization in the EU for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) with or without papillary tumors. The recommendation reflects the EMAs determination that earlier patient access is warranted and represents an important step forward for individuals with BCG-unresponsive disease an area with otherwise limited treatment options. Learn more:" [X Link](https://x.com/ImmunityBio/status/1999453046145962043) 2025-12-12T12:15Z 16.4K followers, 59.4K engagements "The European Medicines Agency has granted conditional marketing authorization for ANKTIVA + BCG for patients with BCG-unresponsive NMIBC CIS in the European Union. This gives eligible patients in the EU access to our innovative treatment. Once the European Commission (EC) gives its final approval it will broadly expand the reach of ANKTIVA from two to [--] nations including the U.K. and U.S. Learn more:" [X Link](https://x.com/ImmunityBio/status/2002059131621159268) 2025-12-19T16:51Z 16.4K followers, [----] engagements "New data demonstrates that ANKTIVA enhances immune restoration when combined with checkpoint inhibitors in NSCLC with statistically significant increases in absolute lymphocyte counts and corresponding survival benefits that reinforce its role as a promising lymphocyte-stimulating agent. Read more: https://immunitybio.com/immunitybio-announces-positive-results-demonstrating-anktiva-as-a-lymphocyte-stimulating-agent-in-combination-with-checkpoint-inhibitors-in-non-small-cell-lung-cancer/" [X Link](https://x.com/ImmunityBio/status/2011091623774732505) 2026-01-13T15:03Z 16.4K followers, 59.7K engagements "Today the Saudi Food and Drug Authority (SFDA) granted accelerated approval of ANKTIVA for use in combination with immune checkpoint inhibitors for adult patients with metastatic NSCLC whose disease has progressed following standard-of-care therapy. This marks the first approval anywhere in the world for ANKTIVA in this indication. Learn more: https://immunitybio.com/saudi-fda-grants-accelerated-approval-to-immunitybios-anktiva-in-combination-with-checkpoint-inhibitors-for-metastatic-non-small-cell-lung-cancer/" [X Link](https://x.com/ImmunityBio/status/2011461005058986417) 2026-01-14T15:30Z 16.4K followers, 14.3K engagements "At ImmunityBio we reported approximately $113 million in preliminary net product revenue for [----] representing a 700% year-over-year increase. This continued momentum reflects steady execution and growing adoption of ANKTIVA - and most importantly progress toward our mission to advance therapies designed to restore the bodys natural ability to fight cancer. Read more: https://immunitybio.com/immunitybio-reports-continued-execution-and-sales-momentum-with-113-million-of-preliminary-net-product-revenue-a-700-increase-year-over-year/" [X Link](https://x.com/ImmunityBio/status/2011822698259677511) 2026-01-15T15:28Z 16.4K followers, 14.5K engagements "Dr. Patrick Soon-Shiong ImmunityBio's Founder Executive Chairman and Global Chief Scientific and Medical Officer also met with His Excellency Dr Bandar Alknawy to discuss the role of King Abdullah International Medical Research Center (KAIMRC) in advancing Saudi Arabias National Biotechnology Strategy. Their conversation highlighted how KAIMRC is contributing to scientific innovation health resilience and long-term economic growth key pillars of Vision [----]. Together these efforts reflect a shared commitment to strengthening international research capabilities and positioning biotechnology as" [X Link](https://x.com/ImmunityBio/status/2011894640908402965) 2026-01-15T20:13Z 16.4K followers, 33.8K engagements "ImmunityBio reported that median overall survival has not yet been reached in patients with recurrent or progressive glioblastoma treated with a chemo-free ANKTIVA + CAR-NK-based regimen. As recent @AmericanCancer data shows that brain cancer is now the third leading cause of cancer-related death among adults ages [----] these findings underscore the urgency of continued innovation in this disease. Read more: https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-reports-median-overall-survival-not-yet-reached-andfield_nir_news_date_value%5Bmin%5D=" [X Link](https://x.com/ImmunityBio/status/2014674465934672001) 2026-01-23T12:19Z 16.4K followers, 105.9K engagements "Firefighters face danger every day both visible and unseen. Research has shown that firefighters are at an increased risk for certain cancers including bladder cancer making awareness and timely diagnosis critical. Our advancements in bladder cancer are guided by a mission to improve outcomes and expand treatment possibilities. Learn more about what ImmunityBio is doing in the bladder cancer space: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/" [X Link](https://x.com/ImmunityBio/status/2015810146501575044) 2026-01-26T15:32Z 16.4K followers, [----] engagements "At this weeks MAHA Media Hub Dr. Patrick Soon-Shiong Founder Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio shared insights on the evolving understanding of cancer and why advancing beyond traditional treatment paradigms is essential. His perspective underscored the importance of rethinking how we approach cancer with a focus on science-driven innovation and the bodys own immune system as a critical part of the solution. Watch now: https://immunitybio.com/maha-action-media-hub/ https://immunitybio.com/maha-action-media-hub/" [X Link](https://x.com/ImmunityBio/status/2017279647512203655) 2026-01-30T16:52Z 16.4K followers, 18.4K engagements "World Cancer Day serves as a reminder of the determination resilience and strength behind every cancer patient's journey - and the importance of continued progress in care. Our work is driven by the responsibility to move cancer research forward to deliver meaningful outcomes and help shape a more hopeful future for patients. https://twitter.com/i/web/status/2019082540792127800 https://twitter.com/i/web/status/2019082540792127800" [X Link](https://x.com/ImmunityBio/status/2019082540792127800) 2026-02-04T16:16Z 16.4K followers, [----] engagements "Progress in non-muscle invasive bladder cancer (NMIBC) depends on continued innovation in how the disease is treated and managed over time. As patients and healthcare providers navigate complex care decisions ImmunityBio is advancing new therapeutic approaches designed to support improved outcomes. Learn more: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/" [X Link](https://x.com/ImmunityBio/status/2013682082979971273) 2026-01-20T18:36Z 16.5K followers, 11K engagements "At ImmunityBio our pipeline continues to expand with chemotherapy-free approaches designed to harness the power of one's own immune system. We have launched ResQ215B a Phase [--] clinical study evaluating a novel chemotherapy-free and lymphodepletion-free combination immunotherapy in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) including Waldenstrms Macroglobulinemia. Learn more: https://immunitybio.com/immunitybio-launches-phase-2-chemotherapy-free-car-nk-cell-therapy-trial-with-anktiva%ef%83%92-resq215b-in-indolent-lymphomas/" [X Link](https://x.com/ImmunityBio/status/2018342629021520023) 2026-02-02T15:15Z 16.5K followers, 61.3K engagements "ImmunityBio Founder Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong recently joined the @OncBrothers podcast to explore the science and patient impact behind what it takes to be a true game-changer in oncology. This wasnt just a discussion about a drug but a conversation about rebuilding the immune system and rethinking what the future of cancer care must look like. Listen in and hear how ImmunityBio is pushing immunotherapy forward starting with the immune system itself: https://www.youtube.com/watchv=aRDyqswYUOY&t=4s" [X Link](https://x.com/ImmunityBio/status/2020954289003499612) 2026-02-09T20:13Z 16.5K followers, 94.8K engagements "As a company that believes medicine should not only treat but transform lives we pursue outcomes that matter. Our team is deeply connected to this mission many of us driven by personal experiences that fuel our commitment. In every breakthrough there is a shared drive to make a difference - because for us this work is personal. https://twitter.com/i/web/status/2022395824358257024 https://twitter.com/i/web/status/2022395824358257024" [X Link](https://x.com/ImmunityBio/status/2022395824358257024) 2026-02-13T19:41Z 16.5K followers, [----] engagements "Weve announced that our initial data shows 100% disease control in [--] out of [--] patients with recurrent glioblastoma after being treated with our ANKTIVA NK cell therapy plus the Optune Gio device. Read more: https://immunitybio.com/initial-data-shows100-disease-control-in-5-out-of-5-patients-with-recurrent-glioblastoma-with-two-patients-in-near-complete-response-treated-with-immunitybios-anktiva-nk-cell-therapy-p/" [X Link](https://x.com/anyuser/status/1960322847512912375) 2025-08-26T12:46Z 16.5K followers, 37.6K engagements "Thrilled about the news that our partners Drs. Hotez and Bottazzi have been nominated for the Nobel Prize for their work on low-cost #COVID-19 vaccine thats already in use in India. Congratulations on the well-deserved recognition @TexasChildrens @PeterHotez @mebottazzi" [X Link](https://x.com/anyuser/status/1494075115440586755) 2022-02-16T22:24Z 16.5K followers, [---] engagements "The team at ImmunityBio extends our congratulations to Dr. Mary E. Brunkow Dr. Fred Ramsdell and Dr. Shimon Sakaguchi recipients of the [----] Nobel Prize in Physiology or Medicine. This groundbreaking research on regulatory T cells has advanced the scientific understanding of immune tolerance providing the foundation for developing novel therapies targeting cancer and infectious diseases. We recognize and applaud their contributions to immunology which continue to inspire innovation. Read more: https://www.nobelprize.org/prizes/medicine/2025/press-release/" [X Link](https://x.com/anyuser/status/1975933479604154618) 2025-10-08T14:37Z 16.5K followers, [----] engagements "We've announced our new study called COVID-4.019-Long which further expands our clinical research efforts to assess ANKTIVAs potential beyond cancer or cancer-related diseases. Learn more about the study and its potential impact: https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-phase-2-study-anktivar-patients-long-covidfield_nir_news_date_valuemin= https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-phase-2-study-anktivar-patients-long-covidfield_nir_news_date_valuemin=" [X Link](https://x.com/anyuser/status/1957786038698668359) 2025-08-19T12:45Z 16.4K followers, 19.2K engagements "We announced early results from our QUILT-106 Phase I trial showing complete responses in the first two late-stage Non-Hodgkin Waldenstrm lymphoma patients treated with our CD19 CAR-NK cell therapy. Learn more: https://immunitybio.com/immunitybio-reports-complete-responses-in-non-hodgkin-waldenstrom-lymphoma-patients-with-chemotherapy-free-first-in-class-cd19-car-nk-immunotherapy/ https://immunitybio.com/immunitybio-reports-complete-responses-in-non-hodgkin-waldenstrom-lymphoma-patients-with-chemotherapy-free-first-in-class-cd19-car-nk-immunotherapy/" [X Link](https://x.com/anyuser/status/1955618969018388527) 2025-08-13T13:14Z 16.5K followers, 96.5K engagements "We've announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the use of our Cancer BioShield platform anchored by ANKTIVA to treat lymphopenia in adult patients with refractory or relapsed solid tumors who have progressed after first-line standard-of-care treatment chemotherapy radiation or immunotherapy. Learn more: https://immunitybio.com/immunitybio-receives-fda-expanded-access-authorization-for-landmark-treatment-of-lymphopenia-with-anktiva-the-cancer-bioshield-platform-in-patients-with-solid-tumors/" [X Link](https://x.com/anyuser/status/1929541052643582012) 2025-06-02T14:10Z 16.5K followers, 10.2K engagements "Weve announced new paradigm-changing findings from the Phase [--] QUILT-3.055 study demonstrating ANKTIVA (nogapendekin alfa inbakicept-pmln) reverses lymphopenia (low natural killer and T cells) in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer (NSCLC) with this reversal resulting in significant prolonged median overall survival (mOS). Read more: https://immunitybio.com/immunitybios-anktiva-reverses-lymphopenia-and-extends-overall-survival-in-patients-with-advanced-non-small-cell-lung-cancer-resistant-to-checkpoint-therapy/" [X Link](https://x.com/anyuser/status/1965043802164654466) 2025-09-08T13:25Z 16.5K followers, 13.3K engagements "At ImmunityBio we're redefining cancer care. Our mission focuses on developing treatments that are not only effective but also aim to enhance patient comfort. Our team works to improve the experiences of those undergoing cancer treatment offering hope through innovative therapies. Learn more about our vision: https://immunitybio.com/founders-vision/ https://immunitybio.com/founders-vision/" [X Link](https://x.com/anyuser/status/1929901465193328702) 2025-06-03T14:02Z 16.5K followers, [----] engagements "Today we announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted the first marketing approval outside the United States for this novel lymphocyte-stimulating agent ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Gurin (BCG) for the treatment of certain bladder cancer patients. Learn more: https://immunitybio.com/uk-mhra-approves-immunitybios-anktiva-plus-bcg-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-carcinoma-in-situ/" [X Link](https://x.com/anyuser/status/1942403512689635618) 2025-07-08T02:01Z 16.5K followers, [----] engagements "Our scientists are working to develop remarkable new therapies that harness the body's inherent power by amplifying both the innate and adaptive branches of the immune system facilitating the attack and elimination of cancerous or infected cells today while building immunological memory for tomorrow. Learn more: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/" [X Link](https://x.com/anyuser/status/1943318052667576663) 2025-07-10T14:35Z 16.5K followers, [----] engagements "Weve reported a 60% revenue increase in Q2 [----] with year-to-date sales reaching $43M and a 246% growth in ANKTIVA sales since J-code issuance. Regulatory milestones continue to help us advance our mission of improving outcomes for patients. Read more: https://immunitybio.com/immunitybio-reports-60-increase-in-revenue-in-q2-2025-with-year-to-date-sales-of-43-million-and-246-unit-growth-since-j-code-with-regulatory-updates/ https://immunitybio.com/immunitybio-reports-60-increase-in-revenue-in-q2-2025-with-year-to-date-sales-of-43-million-and-246-unit-growth-since-j-code-with-regulatory-updates/" [X Link](https://x.com/anyuser/status/1948779388235120803) 2025-07-25T16:16Z 16.5K followers, [----] engagements "Dr. Patrick Soon-Shiong presented groundbreaking insights on harnessing NK cells and memory T cells to fight urological cancers today at the #AUA2025 Innovation Nexus. Were honored to collaborate with healthcare professionals in advancing treatments for bladder cancer" [X Link](https://x.com/anyuser/status/1915865794623471800) 2025-04-25T20:29Z 16.5K followers, [----] engagements "ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patients immune system not weakening it. View our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/" [X Link](https://x.com/ImmunityBio/status/1975225789219242102) 2025-10-06T15:45Z 16.4K followers, [----] engagements "We announced the signing of a strategic Memorandum of Understanding (MOU) to introduce the FDA-approved Cancer BioShield platform to Saudi Arabia and the broader Middle East. Learn more: https://immunitybio.com/immunitybio-saudi-arabias-ministry-of-investment-kfshrc-and-kaimrc-sign-strategic-memorandum-of-understanding-to-launch-cancer-bioshieldtm-platform-in-the-middle-east/ https://immunitybio.com/immunitybio-saudi-arabias-ministry-of-investment-kfshrc-and-kaimrc-sign-strategic-memorandum-of-understanding-to-launch-cancer-bioshieldtm-platform-in-the-middle-east/" [X Link](https://x.com/anyuser/status/1927365940112433441) 2025-05-27T14:07Z 16.5K followers, 10.6K engagements "Lymphopenia is a serious condition affecting many patients with cancer - especially those undergoing chemotherapy or radiation. It can leave the immune system compromised and limit the body's ability to fight illness. We're working to address this challenge through our science and ongoing clinical research with a goal of improving outcomes by enhancing immune recovery. https://twitter.com/i/web/status/1937512789037449583 https://twitter.com/i/web/status/1937512789037449583" [X Link](https://x.com/anyuser/status/1937512789037449583) 2025-06-24T14:07Z 16.5K followers, [----] engagements "This weekend's BCAN Patient Summit in Columbus brought together patients caregivers and healthcare professionals united in their commitment to improving outcomes and quality of life for those affected by bladder cancer. We're proud to stand alongside @BladderCancerUS and the broader advocacy community in this mission. https://twitter.com/i/web/status/1980289869403533722 https://twitter.com/i/web/status/1980289869403533722" [X Link](https://x.com/anyuser/status/1980289869403533722) 2025-10-20T15:07Z 16.5K followers, [----] engagements "We reported another quarter of strong results driven by increased demand for ANKTIVA and continued progress across our immunotherapy pipeline. In Q3 [----] we achieved significant year-to-date unit growth of 467% and $75 million in total product sales reflecting growing adoption in BCG-unresponsive non-muscle invasive bladder cancer. As we close out the year we remain committed to expanding access to our therapies advancing ongoing trials across multiple indications and executing our long-term vision to transform how cancer is treated. Read the full release including important cautionary" [X Link](https://x.com/anyuser/status/1986499820576801050) 2025-11-06T18:23Z 16.5K followers, [----] engagements "We believe our science has the potential to change the current paradigm of care for patients. Through a combination of highly experienced and talented people deep scientific knowledge and advanced research and manufacturing facilities ImmunityBio aims to improve outcomes for those living with difficult-to-treat diseases. Learn more about our founder's vision: https://immunitybio.com/founders-vision/ https://immunitybio.com/founders-vision/" [X Link](https://x.com/anyuser/status/1952429339519435237) 2025-08-04T18:00Z 16.5K followers, [----] engagements "Annually over [------] people in the United States are diagnosed with lung cancer with the majority facing non-small cell lung cancer (NSCLC). We're working to enhance the activity of NK and T cells empowering the immune system to better combat NSCLC. Learn more about our approach: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/" [X Link](https://x.com/anyuser/status/1935701854182351180) 2025-06-19T14:11Z 16.5K followers, [----] engagements "Join us in transforming the future of cancer treatment. ImmunityBio is advancing innovative therapies that bring new hope to patients facing some of the most challenging cancers. We're looking for passionate mission-driven individuals to grow with us. Be a part of something bigger. Explore open positions and apply today: https://immunitybio.com/careers/ https://immunitybio.com/careers/" [X Link](https://x.com/anyuser/status/1938252171390423075) 2025-06-26T15:05Z 16.5K followers, [----] engagements "Yesterdays investor meeting was an important moment to align with key opinion leaders and shareholders on our continued progress toward delivering better treatment options for patients" [X Link](https://x.com/anyuser/status/1912514627252183516) 2025-04-16T14:33Z 16.5K followers, [----] engagements "Were thrilled to announce today @US_FDA approved a first-in-class treatment for BCG-unresponsive non-muscle invasive bladder cancer #NMIBC. Learn more: $IBRX https://immunitybio.com/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer/ https://immunitybio.com/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer/" [X Link](https://x.com/anyuser/status/1782593275725316140) 2024-04-23T02:12Z 16.5K followers, [----] engagements "At ImmunityBio we're dedicated to pushing the boundaries of medical research. By participating in our clinical trials individuals help us innovate and shape the future of cancer and infectious disease treatment. Learn more: https://immunitybio.com/find-a-trial/ https://immunitybio.com/find-a-trial/" [X Link](https://x.com/ImmunityBio/status/1982830206407831709) 2025-10-27T15:22Z 16.4K followers, [----] engagements "Veterans are at an increased risk for bladder cancer due to exposure to carcinogens during service. Houston's Michael E. DeBakey VA Medical Center is now among the first VA hospitals to offer ANKTIVA for eligible veterans with BCG-unresponsive NMIBC. Read more: https://immunitybio.com/immunitybio-announces-houstons-michael-e-debakey-va-medical-center-is-among-the-first-va-hospitals-to-administer-anktiva-to-bladder-cancer-patients/" [X Link](https://x.com/anyuser/status/1954909747788058839) 2025-08-11T14:16Z 16.5K followers, [----] engagements "The FDA has granted ImmunityBio a Regenerative Medicine Advanced Therapy designation to evaluate whether ANKTIVA and CAR-NK can reverse lymphopenia in patients undergoing standard-of-care chemotherapy for locally advanced or metastatic pancreatic cancer. Learn more about our innovative approach to addressing this unmet need in cancer: https://immunitybio.com/immunitybio-receives-fda-rmat-designation-for-anktiva-and-car-nk-for-the-reversal-of-lymphopenia-in-patients-receiving-standard-of-care-chemotherapy-radiotherapy-and-in-treatment-of-multiply-rel/" [X Link](https://x.com/anyuser/status/1895267871821046081) 2025-02-28T00:20Z 16.5K followers, [----] engagements "On this International Clinical Trials Day we at ImmunityBio are dedicated to transforming the future of cancer treatment. This journey wouldn't be possible without the invaluable contributions of our clinical trial participants. Together we are pioneering breakthroughs" [X Link](https://x.com/anyuser/status/1924849754321912015) 2025-05-20T15:28Z 16.5K followers, [----] engagements "We're focused on innovating beyond standard treatments so that we can give the body the tools it needs to lead its own fight against cancer. Learn more about our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/" [X Link](https://x.com/anyuser/status/1962884518085546219) 2025-09-02T14:25Z 16.5K followers, [----] engagements "Lymphopenia remains a critical challenge for patients undergoing cancer treatment often compromising immune function and increasing the risk of complications. At ImmunityBio we are advancing clinical research aimed at promoting immune system recover and improving long-term outcomes for patients. Learn more: https://immunitybio.com/lymphopenia/ https://immunitybio.com/lymphopenia/" [X Link](https://x.com/anyuser/status/1950279918555975787) 2025-07-29T19:39Z 16.5K followers, [----] engagements "Our robust pipeline of clinical trials is all about turning insights into better outcomes for people facing a wide range of cancers. The ImmunityBio team remains committed to transforming research into tangible impact in the lives of patients. Explore our latest trials: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/" [X Link](https://x.com/anyuser/status/1955297290224378015) 2025-08-12T15:56Z 16.5K followers, [----] engagements "Join us now at the product theater where Dr. Patrick Soon-Shiong is presenting our innovative approach to addressing the BCG shortage in bladder cancer. Learn how were advancing therapeutics for better patient outcomes" [X Link](https://x.com/anyuser/status/1916593375744057580) 2025-04-27T20:40Z 16.5K followers, [----] engagements "According to the American Cancer Society lung cancer accounts for nearly [--] in [--] cancer deaths in the United States. ImmunityBio is focused on developing therapies that address this ongoing health challenge. Read more: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/" [X Link](https://x.com/anyuser/status/1945128385400987918) 2025-07-15T14:28Z 16.5K followers, [----] engagements "Bladder cancer recurrence is a reality for nearly half of patients with non-muscle invasive disease. ImmunityBio is advancing immunotherapy-based research to help the body's own defenses recognize and fight cancer. Learn more: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/" [X Link](https://x.com/anyuser/status/1940406193060721095) 2025-07-02T13:44Z 16.5K followers, [----] engagements ""Smart therapies for difficult diseases" isn't just a phrase - it is the foundation of everything we do. At ImmunityBio we're working to transform how cancer is treated by designing therapies that not only target disease but restore the body's natural ability to fight it. View our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/" [X Link](https://x.com/anyuser/status/1934622981357253104) 2025-06-16T14:43Z 16.5K followers, [----] engagements "Lung cancer remains one of the leading causes of cancer-related deaths worldwide. At ImmunityBio we are advancing clinical research to explore new treatment options that harness the immune system. Our goal is to help expand possibilities for patients facing this disease. Learn more about our research: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/" [X Link](https://x.com/ImmunityBio/status/1970920651419681051) 2025-09-24T18:37Z 16.4K followers, [----] engagements "Today we announced our first patient dosed in our recombinant BCG (rBCG) FDA-authorized Expanded Access Program. With [--] sites launching providers like U.S. Urology Partners are helping address the nationwide BCG shortage. Learn more: https://immunitybio.com/immunitybio-announces-first-dosing-of-recombinant-bcg-rbcg-in-the-u-s-and-60-sites-in-the-process-of-launching/ https://immunitybio.com/immunitybio-announces-first-dosing-of-recombinant-bcg-rbcg-in-the-u-s-and-60-sites-in-the-process-of-launching/" [X Link](https://x.com/anyuser/status/1900184441634652624) 2025-03-13T13:57Z 16.5K followers, [----] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@ImmunityBio ImmunityBio, Inc.
ImmunityBio, Inc. posts on X about future, in the, hope, we are the most. They currently have [---------] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.
Engagements: [-----] #
- [--] Week [------] +222%
- [--] Month [-------] +328%
- [--] Months [-------] +293%
- [--] Year [-------] +367%
Mentions: [--] #
- [--] Week [--] +81%
- [--] Month [--] +48%
- [--] Months [--] +1.40%
- [--] Year [---] +83%
Followers: [---------] #
- [--] Week [------] +1.50%
- [--] Month [------] +17%
- [--] Months [------] +55%
- [--] Year [------] +426%
CreatorRank: [-------] #
Social Influence
Social category influence countries finance travel destinations ncaa football ncaa basketball
Social topic influence future, in the, hope, we are, science #4764, the first, united states, health, $ibrx #10, approval
Top accounts mentioned or mentioned by @petitnong_ @drpatrick @phoenxlights @jayosays @saiseiinvesting @bladdercancerus @urocancermd @drpatsoonshiong @oshin76 @foreveruseless_ @garyr9912 @xrphomie @usfda @urologytimes @urologycarefdn @meeradnan89945 @epboston @maschotta_adam @truedat999 @amerurological
Top assets mentioned ImmunityBio, Inc. Common Stock (IBRX)
Top Social Posts
Top posts by engagements in the last [--] hours
"ImmunityBio has reached many important milestones this year we owe that progress to our extended family of trial investigators & fellow scientists trial volunteers our partners & our dedicated employees. Wishing you & your families a joyous holiday season❤"
X Link 2022-12-22T22:56Z [----] followers, [----] engagements
"We're #Hiring: Clinical Research Associate Join our experienced mission-driven team thats working to give new hope and a better quality of life to millions of patients around the world. Visit our #Careers page to learn more: #BiotechJobs"
X Link 2023-08-25T20:10Z [----] followers, [---] engagements
"At ImmunityBio our goal is to engage & enhance the immune systems natural ability to fight even difficult-to-treat diseases creating better treatments for better outcomes. Learn more about our research and #clinicaltrials: #CancerVaccine #immunotherapy"
X Link 2023-08-28T16:48Z [----] followers, [---] engagements
"We're #Hiring: Senior Facilities Planner Join our experienced mission-driven team thats working to give new hope and a better quality of life to millions of patients around the world. Visit our #Careers page to learn more: #BiotechJobs"
X Link 2023-08-30T21:31Z [----] followers, [---] engagements
"We're #Hiring: Manager QCA Potency Assay and Trending Join our experienced mission-driven team thats working to give new hope and a better quality of life to millions of patients around the world. Visit our #Careers page to learn more: #BiotechJobs"
X Link 2023-09-09T00:14Z [----] followers, [---] engagements
"#LynchSyndrome increases the risk of various cancers for people living with it. That's why we're working w/ @theNCI on a clinical study using our investigational therapies to prevent related cancers. Learn more about the inherited condition: via @TODAYshow"
X Link 2023-09-20T22:45Z [----] followers, [---] engagements
"Last year researchers from @WUSTLmed published data in @ScienceTM on Natural Killer Cells. This data further demonstrates the potential use of memory-like NK cells plus N-803 for treating cancer: #CancerResearch #immunotherapy"
X Link 2023-10-18T21:13Z [----] followers, [---] engagements
"Today we announced that @US_FDA has accepted for review our BLA resubmission for N-803 plus BCG for BCG-unresponsive NMIBC. New PDUFA date is April [--] [----]. Full press release: $IBRX #NMIBC"
X Link 2023-10-26T14:23Z [----] followers, [----] engagements
"In Case You Missed It: Last week we had the opportunity to participate in the 35th Annual @Piper_Sandler Healthcare Conference. Watch a replay of the presentation here: $IBRX #immunotherapy #CancerResearch"
X Link 2023-12-05T17:21Z [----] followers, [---] engagements
"February 1st marks the beginning of #BlackHistoryMonth ImmunityBio celebrates the Black pioneers in medicine and recognizes their groundbreaking achievements for the Urology community. Visit this article created by #AUA and #UCF to learn more:"
X Link 2024-02-01T16:40Z [----] followers, [---] engagements
"Dive into the latest research and advancements in urology with us at #AUA24 Join ImmunityBio at the @AmerUrological annual meeting in San Antonio May 3-6. Find us at booth #1931. More info: #Urology #AUAMembers"
X Link 2024-02-28T17:08Z [----] followers, [---] engagements
"#ChapelHill @BCAN #Bladdercancer Walk: ImmunityBio is proud to co-sponsor the BCAN Walk to End Bladder Cancer. Thank you BCAN for the important work you do everyday on behalf of bladder cancer patients and their caregivers"
X Link 2024-04-27T21:07Z [----] followers, [----] engagements
"Join us at #AUA24 for a groundbreaking discussion on next-gen immunotherapy for bladder cancer with @UroCancerMD and @DrPatSoonShiong. Details: Friday. 5/3 @ 3:15 CDT in the Learning Lab at AUA Square. #NMIBC #Immunotherapy"
X Link 2024-05-01T23:23Z [----] followers, [----] engagements
"Attending #AUA24 Dive into the future of bladder cancer treatment with ImmunityBio founder @DrPatSoonShiong and @UroCancerMD. Learn how Anktiva revolutionizes therapy approaches tomorrow May [--] @ 3:15 CDT in the Learning Lab at AUA Square. #BladderCancer #Immunotherapy"
X Link 2024-05-02T16:19Z [----] followers, [---] engagements
"🚨On the heels of the FDA approval of our combination therapy for treatment of #NMIBC ImmunityBio and @seruminstindia have agreed to an exclusive arrangement for global supply of BCG. Read More: https://immunitybio.com/immunitybio-serum-institute-of-india-agree-on-an-exclusive-arrangement-for-global-supply-of-bacillus-calmette-guerin-bcg-across-all-cancer-types https://immunitybio.com/immunitybio-serum-institute-of-india-agree-on-an-exclusive-arrangement-for-global-supply-of-bacillus-calmette-guerin-bcg-across-all-cancer-types"
X Link 2024-05-02T21:08Z 16.5K followers, [----] engagements
"Hear from @DrPatSoonShiong himself on the potential of Anktiva in battling bladder cancer alongside @UroCancerMD at #AUA24. Join them today @ 3:15 CDT at the Learning Lab at AUA Square for an illuminating discussion. #BladderCancer #NMIBC"
X Link 2024-05-03T15:34Z [----] followers, [----] engagements
"Don't miss out 3:15 CDT at the Learning Lab at AUA Square: @DrPatSoonShiong's in-depth conversation with @UroCancerMD on the potential of Anktiva in battling #BladderCancer. #AUA24 #NMIBC http://bit.ly/4ddHQEK http://bit.ly/4ddHQEK"
X Link 2024-05-03T19:29Z [----] followers, [----] engagements
"ICYMI: AUA Daily News covered @drpatrick 's fireside chat with Dr. Sam Chang @UroCancerMD at #AUA2024"
X Link 2024-05-05T00:13Z 16.5K followers, [----] engagements
"ImmunityBios state-of-the-art GMP biological manufacturing facility in Dunkirk New York https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-completes-gmp-drug-substance-manufacturingfield_nir_news_date_valuemin= https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-completes-gmp-drug-substance-manufacturingfield_nir_news_date_valuemin="
X Link 2024-05-07T14:59Z 16.5K followers, [----] engagements
"We're pleased to announce we've completed GMP drug substance manufacturing sufficient for [------] doses of our newly approved treatment. Exciting times ahead https://shorturl.at/MOW08 https://shorturl.at/MOW08"
X Link 2024-05-07T17:30Z 16.5K followers, [----] engagements
"ImmunityBio is at the forefront of transforming bladder cancer treatment. Our innovative research aims to develop more effective therapies. Visit us to learn about our groundbreaking work and how we're making a difference: #BladderCancer #ImmunityBio https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2024-05-09T22:05Z 16.5K followers, [----] engagements
"Did you know #BladderCancer is the 4th most commonly diagnosed cancer among veterans. #BladderCancerAwareness month is more than a hashtag it's a call to action for sharing vital info & honoring the resilience of those who've served our country. #MemorialDay @BladderCancerUS"
X Link 2024-05-27T14:51Z [----] followers, [----] engagements
"ImmunityBio founder @DrPatSoonShiong shared his remarkable journey on the #HealthcareUnfiltered podcast. From apartheid-era South Africa to global success he overcame adversity pioneered cancer treatments and continues to make a difference. Listen: https://tinyurl.com/5n8bm59n https://tinyurl.com/5n8bm59n"
X Link 2024-07-16T14:41Z [----] followers, [----] engagements
"If you are passionate about our mission to develop innovative therapies that target some of the most difficult-to-treat human diseases consider joining our expanding team of talented professionals. View our #OpenPositions here: https://immunitybio.com/careers/ https://immunitybio.com/careers/"
X Link 2024-07-22T18:53Z [----] followers, [----] engagements
"Our CTO Enrique Dilon Ph.D. recently spoke with @BioProcessOL @mattpillar about his role and the company-wide decisions that go into the transition from FDA approval to the commercialization of Anktiva. Listen here: #BusinessOfBiotech https://shorturl.at/Np9cw https://shorturl.at/Np9cw"
X Link 2024-07-23T15:21Z [----] followers, [----] engagements
"Today is #WorldLungCancerDay. At ImmunityBio were pioneering advanced immunotherapy treatments to bolster immune responses and improve outcomes. Together we can make a difference. Learn more: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2024-08-01T15:12Z [----] followers, [----] engagements
"Today we announced that we are studying ANKTIVA in combination with the investigational AdHER2DC cancer vaccine as a potential treatment for endometrial cancer aiming to improve outcomes and sustain clinical response. Learn more: https://immunitybio.com/immunitybio-announces-study-of-anktiva-in-combination-with-the-adher2dc-cancer-vaccine-as-a-potential-therapy-to-control-endometrial-cancer https://immunitybio.com/immunitybio-announces-study-of-anktiva-in-combination-with-the-adher2dc-cancer-vaccine-as-a-potential-therapy-to-control-endometrial-cancer"
X Link 2024-08-06T13:09Z [----] followers, [----] engagements
"We look forward to attending the @BladderCancerUS Think Tank Program. As we continue to strive for advancements in bladder cancer therapies we are committed to pioneering new treatments that enhance patient outcomes. #BCANThinkTank"
X Link 2024-08-07T14:47Z [----] followers, [----] engagements
"According to @BladderCancerUS a firefighter's prolonged exposure to harmful chemicals increases their risk of being diagnosed with #BladderCancer. ImmunityBio recognizes the urgent need to prevent surgical removal of the bladder. Read more: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2024-08-19T14:32Z [----] followers, [----] engagements
"Our research in oncology and infectious diseases aims to provide patients with hope for better outcomes and improved quality of life. Learn more about our approach: https://immunitybio.com/patients https://immunitybio.com/patients"
X Link 2024-08-21T15:09Z [----] followers, [----] engagements
"ImmunityBio's mission is to address unmet needs in #Oncology and #InfectiousDisease by leveraging the patient's own immune system to not only fight illness but offer long-term protection. Learn more: https://immunitybio.com/about/ https://immunitybio.com/about/"
X Link 2024-08-23T14:35Z [----] followers, [----] engagements
"The ImmunityBio team looks forward to joining researchers healthcare professionals and advocacy partners at the New England AUA Sectional. #BladderCancerResearch"
X Link 2024-09-05T14:34Z [----] followers, [----] engagements
"Despite #LungCancer being one of the most common cancers worldwide there are very few successful treatment options once the cancer spreads beyond the lungs. We strive make advancements in #NSCLC treatments. Learn more: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2024-09-16T13:40Z [----] followers, [----] engagements
"Were studying ANKTIVA in combination with the current standard of care vs. standard of care as first-line treatment for patients with stage [--] or [--] non-small cell lung cancer (NSCLC). Learn more about our phase [--] trial: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2024-10-11T14:24Z [----] followers, [----] engagements
"Were looking forward to participating in the Jefferies London Healthcare Conference [----] taking place November [----] and marking the 15th anniversary of the largest healthcare-dedicated conference in Europe. Learn more: #JefferiesHealthcare https://immunitybio.com/immunitybio-to-participate-in-the-jefferies-london-healthcare-conference-2/ https://immunitybio.com/immunitybio-to-participate-in-the-jefferies-london-healthcare-conference-2/"
X Link 2024-10-21T13:26Z 11.5K followers, [----] engagements
"As part of our patient recruitment efforts we are working with advocacy groups and community leaders to raise awareness of our trials in communities that have historically not been involved in clinical studies. Learn more: https://immunitybio.com/diversity-equity-and-inclusion/ https://immunitybio.com/diversity-equity-and-inclusion/"
X Link 2024-10-23T15:25Z 11.5K followers, [----] engagements
"ImmunityBio announced the first patients dosed in our Phase I clinical study of CAR-NK therapy for the treatment of relapsed B-Cell non-Hodgkins lymphoma. Learn more: https://immunitybio.com/first-patients-dosed-in-phase-1-clinical-study-of-immunitybios-car-nk-cell-therapy-for-the-treatment-of-relapsed-b-cell-non-hodgkin-lymphoma/ https://immunitybio.com/first-patients-dosed-in-phase-1-clinical-study-of-immunitybios-car-nk-cell-therapy-for-the-treatment-of-relapsed-b-cell-non-hodgkin-lymphoma/"
X Link 2024-10-24T14:31Z 16.5K followers, 30.7K engagements
"We're grateful to join fellow urology experts at the 100th Annual Western Section AUA Meeting. It is collaboration that drives us to innovate therapies that enhance patient outcomes"
X Link 2024-10-29T14:05Z 11.5K followers, [----] engagements
"We recognize the veterans whose sacrifices extend beyond their service. The U.S. Department of Veteran's Affairs reports nearly [----] veterans are faced with a lung cancer diagnosis each year. Learn more about our clinical trial: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2024-11-06T15:21Z [----] followers, [----] engagements
"NMIBC's high recurrence rate is associated with diminished quality of life significant financial burden and greater mortality risk. ImmunityBio understands the critical need for innovative treatment options. Learn more about our studies: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2024-11-08T20:02Z [----] followers, [---] engagements
"ImmunityBio is working towards a future free from fear of cancer. By tapping into the power of the immune system we're innovating therapies that bring new hope to patients and their loved ones. View our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2024-11-12T14:42Z 16.5K followers, [----] engagements
"Immunotherapy is revolutionizing modern medicine and we're proud to be at the forefront of advancing treatment options for cancer. Discover more about our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2024-11-20T15:18Z [----] followers, [----] engagements
"This Thanksgiving we're deeply grateful to our clinical trial participants investigators and dedicated employees. Your contributions drive life-saving innovations bringing hope to patients and families"
X Link 2024-11-28T18:31Z [----] followers, [----] engagements
"We're grateful to attend the 25th Annual @UroOnc Meeting where we will collaborate with leading voices in the bladder cancer space as we work toward transformative advances in treatment"
X Link 2024-12-04T14:59Z [----] followers, [----] engagements
"ImmunityBio is proud to be at the forefront of cancer treatment innovation. Hear from CEO @richadcock as he discusses our novel FDA-approved immunotherapy for BCG-unresponsive NMIBC CIS and transformative investigational therapies for lung cancer and other difficult-to-treat diseases: https://www.onyxnewsroom.com/how-immunitybio-is-transforming-cancer-treatment-in-just-30-seconds-2/ https://www.onyxnewsroom.com/how-immunitybio-is-transforming-cancer-treatment-in-just-30-seconds-2/"
X Link 2024-12-04T19:14Z [----] followers, [----] engagements
"Each year in the U.S. over [------] people are diagnosed with lung cancer with the majority facing non-small cell lung cancer (NSCLC). Our N-803 investigational therapy is designed to enhance the activity of NK and T cells empowering the immune system to better combat NSCLC. Find out more about our approach: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2024-12-10T15:05Z [----] followers, [----] engagements
"@UrologyTimes has named their top [--] videos of [----] including Dr. Patrick Soon-Shiong's interview on ANKTIVA as a treatment for non-muscle invasive bladder cancer carcinoma in situ. Watch here: https://www.urologytimes.com/view/dr-soon-shiong-discusses-the-fda-approval-of-n-803-in-nmibc https://www.urologytimes.com/view/dr-soon-shiong-discusses-the-fda-approval-of-n-803-in-nmibc"
X Link 2024-12-31T22:49Z [----] followers, [---] engagements
"Cancer is the leading cause of death among firefighters with studies showing they are 9% more likely to develop cancer and 14% more likely to die from cancer compared to the general population (National Institute for Occupational Safety and Health). At ImmunityBio we are dedicated to highlighting these risks and advancing outcomes for those impacted by cancer"
X Link 2025-01-10T16:09Z [----] followers, [--] engagements
"During Firefighter Cancer Awareness Month we recognize the unique health challenges firefighters face as a result of the job. Our commitment is to raise awareness about cancer risks and support those who dedicate their lives to our safety. Learn more by visiting the @BladderCancerUS website: https://bcan.org/find-support/firefighters-and-bladder-cancer/ https://bcan.org/find-support/firefighters-and-bladder-cancer/"
X Link 2025-01-13T16:13Z [----] followers, [---] engagements
"With the introduction of a permanent J-code (J9028) for ANKTIVA the billing and reimbursement process is now more efficient for healthcare providers. Learn more: https://immunitybio.com/immunitybio-announces-permanent-j-code-j9028-for-anktiva-is-now-effective/ https://immunitybio.com/immunitybio-announces-permanent-j-code-j9028-for-anktiva-is-now-effective/"
X Link 2025-01-15T16:31Z [----] followers, [----] engagements
"ImmunityBio is advancing our clinical development pipeline to address critical gaps in non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC) treatments with ANKTIVA. Read more: https://immunitybio.com/immunitybio-provides-regulatory-update-on-anticipated-fda-submissions-in-2025-following-meeting-with-the-agency/ https://immunitybio.com/immunitybio-provides-regulatory-update-on-anticipated-fda-submissions-in-2025-following-meeting-with-the-agency/"
X Link 2025-01-16T14:59Z [----] followers, [--] engagements
"ImmunityBio has announced our submission of marketing authorization applications for ANKTIVA to the European Union (EU) European Medicines Agency and the United Kingdoms (UK) Medicines and Healthcare products Regulatory Agency (MHRA). Learn more: https://immunitybio.com/immunitybio-provides-regulatory-update-on-global-submission-for-anktiva-bcg-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer-with-carcinoma-in-situ-in-europe-and-united-kingdom/"
X Link 2025-01-16T15:00Z [----] followers, [----] engagements
"Firefighters: Your health matters. This brave occupation comes with an increased risk of cancer including bladder cancer. Early detection is crucial to improving outcomes; if you're experiencing symptoms like blood in urine frequent urination or pain while urinating talk to your doctor about screening"
X Link 2025-01-17T15:17Z [----] followers, [--] engagements
"The battle against occupational cancer in firefighters starts with awareness and ends with action. Firefighters confront a higher risk of developing bladder cancer and ImmunityBio is committed to advancing treatments that improve outcomes for all affected. Read more about our research: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2025-01-22T15:06Z [----] followers, [---] engagements
"Prolonged exposure to heat toxic smoke and the byproducts of fire have been shown to cause firefighters health issues like cancer heart disease respiratory diseases and more. We aim to shed light on the prevalence of these health risks the firefighter community faces to promote early screening and better outcomes"
X Link 2025-01-24T15:36Z [----] followers, [----] engagements
"ImmunityBio has announced the European Medicine Agencys acceptance of its marketing authorization application for ANKTIVA (in combination with BCG) to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. The application is based on promising results from the QUILT [-----] study marking a significant step forward in offering innovative treatment options to patients worldwide. Learn more: https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-european-medicines-agency-acceptancefield_nir_news_date_valuemin="
X Link 2025-01-27T15:26Z [----] followers, [----] engagements
"The dangers of firefighting don't disappear when the gear comes off. Firefighters face increased risk of developing cancers including bladder cancer due to prolonged exposure to hazardous chemicals on the job. At ImmunityBio we are committed to advancing innovative treatments and improving outcomes for those affected by bladder cancer. Learn more about our efforts to bring hope and better outcomes to firefighters and all those impacted by bladder cancer: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2025-01-28T16:41Z [----] followers, [----] engagements
"Immunityio has partnered with BeiGene (soon to be BeOne Medicines) for a Phase [--] trial aimed at evaluating the efficacy and safety of two immunotherapeutic agents in patients with metastatic non-small cell lung cancer (NSCLC) resistant to immune checkpoint inhibitors. Learn more about this effort to advance treatments for those facing unmet needs in oncology: https://immunitybio.com/immunitybio-announces-collaboration-with-beigene-on-confirmatory-phase-3-trial-of-anktiva-and-pd-1-checkpoint-inhibitor-combination-in-non-small-cell-lung-cancer/"
X Link 2025-01-29T13:43Z 16.5K followers, [----] engagements
"As National Firefighter Cancer Awareness Month comes to a close ImmunityBio extends our heartfelt gratitude to the brave men and women who serve as firefighters. Your courage strength and unwavering commitment inspire us every day. We recognize the unique risks you face including the increased vulnerability to cancers like bladder cancer. That is why we remain steadfast in our mission to improve outcomes for those impacted by this disease. Thank you for protecting our communities"
X Link 2025-01-31T15:08Z [----] followers, [----] engagements
"At ImmunityBio we're focused on transforming the treatment landscape for non-small cell lung cancer with innovative therapies. Explore our approach and learn more: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2025-02-06T14:58Z [----] followers, [----] engagements
"Bladder cancer awareness and education are critical especially for high-risk communities like firefighters. ImmunityBio is proud to sponsor this special edition of UrologyHealth Extra @UrologyCareFdn providing valuable insights and resources for those impacted by bladder cancer. Read more here: https://www.urologyhealth.org/healthy-living/urologyhealth-extra https://www.urologyhealth.org/healthy-living/urologyhealth-extra"
X Link 2025-02-10T23:58Z [----] followers, 16.2K engagements
"Are you looking to help shape the future of cancer treatment ImmunityBio is hiring passionate individuals committed to advancing research and developing innovative therapies. Start your journey with us: https://immunitybio.com/careers/ https://immunitybio.com/careers/"
X Link 2025-02-11T14:37Z [----] followers, [----] engagements
"Advancing cancer research means addressing inherited cancer-causing conditions like Lynch syndrome. ImmunityBio is conducting a clinical trial to explore innovative therapies for those diagnosed with Lynch syndrome. Learn more: https://immunitybio.com/lynch-syndrome/ https://immunitybio.com/lynch-syndrome/"
X Link 2025-02-13T14:58Z [----] followers, [----] engagements
"ImmunityBio announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has validated and accepted the marketing authorization application for ANKTIVA. The agency will now assess ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with bacillus Calmette-Gurin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Learn more:"
X Link 2025-02-13T20:37Z [----] followers, [----] engagements
"Through cutting-edge science and a patient-focused approach ImmunityBio is working to change the future of bladder cancer treatment. See how we're driving progress and delivering new hope to patients: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2025-02-18T15:18Z [----] followers, [----] engagements
"ImmunityBio today announced that the FDA has authorized an Expanded Access Program (EAP) to improve U.S. patient access to BCG a standard-of-care treatment for non-muscle invasive bladder cancer. Learn more: https://immunitybio.com/fda-authorizes-immunitybio-to-provide-recombinant-bcg-rbcg-to-urologists-to-address-tice-bcg-shortage/ https://immunitybio.com/fda-authorizes-immunitybio-to-provide-recombinant-bcg-rbcg-to-urologists-to-address-tice-bcg-shortage/"
X Link 2025-02-19T14:08Z 16.5K followers, 25.3K engagements
"Today we recognize the caregivers who provide support and compassion to patients facing cancer and serious illnesses. Your dedication is invaluable; we thank you for your commitment to those in need"
X Link 2025-02-21T16:08Z [----] followers, [----] engagements
"The FDA has granted ImmunityBio a Regenerative Medicine Advanced Therapy designation to evaluate whether ANKTIVA and CAR-NK can reverse lymphopenia in patients undergoing standard-of-care chemotherapy for locally advanced or metastatic pancreatic cancer. Learn more about our innovative approach to addressing this unmet need in cancer: https://immunitybio.com/immunitybio-receives-fda-rmat-designation-for-anktiva-and-car-nk-for-the-reversal-of-lymphopenia-in-patients-receiving-standard-of-care-chemotherapy-radiotherapy-and-in-treatment-of-multiply-rel/"
X Link 2025-02-28T00:20Z 16.5K followers, [----] engagements
"Colorectal cancer is one of the most common cancers diagnosed in the U.S. and for some the risk is inherited. Up to 3% of all colorectal cancer cases are linked to Lynch syndrome yet many remain unaware of their genetic risk. Identifying Lynch syndrome early on can lead to potentially life-saving interventions. Learn more about the connection between Lynch syndrome and cancer risk: https://immunitybio.com/lynch-syndrome/ https://immunitybio.com/lynch-syndrome/"
X Link 2025-03-03T15:49Z [----] followers, [----] engagements
"Broadening treatment options is critical to advancing care for those affected by complex diseases like non-small cell lung cancer. With each advancement we move closer to more effective personalized approaches that address the unique challenges of these conditions. By focusing on innovation ImmunityBio aims to offer more hope for the patients who need it most. Learn more: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2025-03-05T19:21Z [----] followers, [----] engagements
"Colorectal cancer remains a leading cancer in the U.S. with over [------] diagnosed each year. Lynch syndrome an inherited condition increases the risk of developing colorectal and other cancers. ImmunityBio is working to develop investigational immunotherapy products aimed at treating and preventing cancers associated with Lynch syndrome. Read more: https://immunitybio.com/lynch-syndrome/ https://immunitybio.com/lynch-syndrome/"
X Link 2025-03-11T13:57Z [----] followers, [----] engagements
"Today we announced our first patient dosed in our recombinant BCG (rBCG) FDA-authorized Expanded Access Program. With [--] sites launching providers like U.S. Urology Partners are helping address the nationwide BCG shortage. Learn more: https://immunitybio.com/immunitybio-announces-first-dosing-of-recombinant-bcg-rbcg-in-the-u-s-and-60-sites-in-the-process-of-launching/ https://immunitybio.com/immunitybio-announces-first-dosing-of-recombinant-bcg-rbcg-in-the-u-s-and-60-sites-in-the-process-of-launching/"
X Link 2025-03-13T13:57Z 16.5K followers, [----] engagements
"ImmunityBio is dedicated to transforming the way we fight cancer and infectious diseases by empowering the body's own immune system. Our mission is to not only treat illness but to provide lasting protection that gives patients hope for a healthier future. Learn more about our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-03-18T14:23Z 16.5K followers, [----] engagements
"ImmunityBio is honored to be recognized as one of @FastCompany's most innovative companies of [----]. Innovation is at the core of our mission as we work to develop cutting-edge therapies and create better outcomes for patients. We remain committed to transforming the future of medicine and delivering hope to those in need"
X Link 2025-03-19T13:47Z 16.5K followers, [----] engagements
"Lynch syndrome is the most common inherited cause of colorectal cancer and increases the risk of several other cancer types. At ImmunityBio were committed to advancing research that may offer new hope for individuals with Lynch syndrome including ongoing studies exploring the role of immunotherapy in this high-risk population"
X Link 2025-03-22T21:47Z [----] followers, [--] engagements
"At ImmunityBio our people are the driving force behind everything we do - advancing science supporting clinical research and working towards better treatment options for patients. If you're passionate about making a meaningful difference apply for one of our open positions today: https://immunitybio.com/careers/ https://immunitybio.com/careers/"
X Link 2025-03-24T16:12Z [----] followers, [----] engagements
"Bladder cancer can often go undetected until it has progressed. Early diagnosis and access to new treatment options are critical to improving outcomes for those affected. Learn more about how we're committed to advancing research and exploring new possibilities through our clinical trials: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2025-03-27T13:48Z 16.5K followers, [----] engagements
"Many individuals with Lynch syndrome are unaware that they carry the gene mutation until they're diagnosed with cancer making education early detection and clinical research critically important. Our clinical trial is designed to explore potential treatment options for those with Lynch syndrome. Learn more: https://immunitybio.com/lynch-syndrome/ https://immunitybio.com/lynch-syndrome/"
X Link 2025-03-31T13:54Z 16.5K followers, [----] engagements
"We position ourselves at the forefront of cancer research striving to gain deeper insights and develop more effective treatments for patients. Learn more about our ongoing clinical trials: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-04-02T17:39Z 16.5K followers, [----] engagements
"Field Medical Director Dr. Rachel Elward reflects on the unique fulfillment of working in immunotherapy driven by the potential to transform patient lives. Learn more about our approach: https://immunitybio.com/patients/ https://immunitybio.com/patients/"
X Link 2025-04-08T15:10Z 16.5K followers, [----] engagements
"ImmunityBios latest QUILT [-----] data demonstrates the longest duration of complete response and the highest rate of cystectomy avoidance within the non-muscle invasive bladder cancer space. Watch Dr. Sam Chang's oral presentation here: and explore the most recent data: https://immunitybio.com/unmatched-long-term-bladder-preservation-for-36-months-in-over-80-percent-of-responders-with-anktiva-plus-bcg-in-bcg-unresponsive-nmibc-cis-and-papillary-disease-alone-best-in-disease/ https://vimeo.com/1079187906utm_source=email&utm_medium=vimeo-email&utm_campaign=44349"
X Link 2025-04-28T13:11Z 16.5K followers, [----] engagements
"During Bladder Cancer Awareness Month we at ImmunityBio reflect on our mission to innovate and improve the lives of those battling this disease. Our relentless pursuit of groundbreaking therapies underscores our commitment to delivering hope and better solutions for patients. Learn more by visiting https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2025-05-01T17:16Z 16.5K followers, [----] engagements
"We're focused on driving innovation in bladder cancer care - starting where it's most commonly diagnosed: non-muscle invasive disease. At ImmunityBio advancing treatment options remains a critical priority. Learn more: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2025-05-07T15:19Z 16.5K followers, [----] engagements
"We announced the signing of a strategic Memorandum of Understanding (MOU) to introduce the FDA-approved Cancer BioShield platform to Saudi Arabia and the broader Middle East. Learn more: https://immunitybio.com/immunitybio-saudi-arabias-ministry-of-investment-kfshrc-and-kaimrc-sign-strategic-memorandum-of-understanding-to-launch-cancer-bioshieldtm-platform-in-the-middle-east/ https://immunitybio.com/immunitybio-saudi-arabias-ministry-of-investment-kfshrc-and-kaimrc-sign-strategic-memorandum-of-understanding-to-launch-cancer-bioshieldtm-platform-in-the-middle-east/"
X Link 2025-05-27T14:07Z 16.5K followers, 10.6K engagements
"Advanced ovarian cancer presents significant challenges especially for this with platinum-resistant recurrence. ImmunityBio is working on potential solutions through our clinical trial for recurrent platinum-resistant high-grade ovarian cancer. Our goal is to provide new hope where options are limited. Visit our website to learn more: https://immunitybio.com/ovarian-cancer/ https://immunitybio.com/ovarian-cancer/"
X Link 2025-06-10T16:33Z 16.5K followers, [----] engagements
"At ImmunityBio our commitment to innovation drives us to explore new frontiers in medicine. From addressing genetic disorders like Lynch syndrome to tackling complex cancers such as bladder cancer we are dedicated to making a meaningful impact. Join us in our journey to transform the future of healthcare by viewing our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-06-13T14:30Z 16.5K followers, [----] engagements
"Annually over [------] people in the United States are diagnosed with lung cancer with the majority facing non-small cell lung cancer (NSCLC). We're working to enhance the activity of NK and T cells empowering the immune system to better combat NSCLC. Learn more about our approach: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2025-06-19T14:11Z 16.5K followers, [----] engagements
"The team at ImmunityBio extends our congratulations to Dr. Mary E. Brunkow Dr. Fred Ramsdell and Dr. Shimon Sakaguchi recipients of the [----] Nobel Prize in Physiology or Medicine. This groundbreaking research on regulatory T cells has advanced the scientific understanding of immune tolerance providing the foundation for developing novel therapies targeting cancer and infectious diseases. We recognize and applaud their contributions to immunology which continue to inspire innovation. Read more: https://www.nobelprize.org/prizes/medicine/2025/press-release/"
X Link 2025-10-08T14:37Z 16.5K followers, [----] engagements
"Today we were able to participate in an insightful discussion organized by the Consulate of Denmark (@ICDK_CPH) about innovative ways industry & hospitals are collaborating on #clinicalresearch. We so appreciate the opportunity to take part in these important conversations. #icdk"
X Link 2023-01-20T23:45Z 14.7K followers, [---] engagements
"We are dedicated to conducting inclusive medical research through clinical trials aiming to advance treatments that can benefit all patients in need. Learn more about our efforts: https://immunitybio.com/diversity-equity-and-inclusion/ https://immunitybio.com/diversity-equity-and-inclusion/"
X Link 2025-02-25T16:41Z [----] followers, [----] engagements
"Lymphopenia is a serious condition affecting many patients with cancer - especially those undergoing chemotherapy or radiation. It can leave the immune system compromised and limit the body's ability to fight illness. We're working to address this challenge through our science and ongoing clinical research with a goal of improving outcomes by enhancing immune recovery. https://twitter.com/i/web/status/1937512789037449583 https://twitter.com/i/web/status/1937512789037449583"
X Link 2025-06-24T14:07Z 16.5K followers, [----] engagements
"Join us in transforming the future of cancer treatment. ImmunityBio is advancing innovative therapies that bring new hope to patients facing some of the most challenging cancers. We're looking for passionate mission-driven individuals to grow with us. Be a part of something bigger. Explore open positions and apply today: https://immunitybio.com/careers/ https://immunitybio.com/careers/"
X Link 2025-06-26T15:05Z 16.5K followers, [----] engagements
"Bladder cancer recurrence is a reality for nearly half of patients with non-muscle invasive disease. ImmunityBio is advancing immunotherapy-based research to help the body's own defenses recognize and fight cancer. Learn more: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2025-07-02T13:44Z 16.5K followers, [----] engagements
"On this Independence Day we recognize the sacrifices made for our freedom and the strength of the communities that continue to move our nation forward. The team at ImmunityBio wishes you a safe and happy holiday"
X Link 2025-07-04T17:09Z 16.5K followers, [----] engagements
"Today we announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted the first marketing approval outside the United States for this novel lymphocyte-stimulating agent ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Gurin (BCG) for the treatment of certain bladder cancer patients. Learn more: https://immunitybio.com/uk-mhra-approves-immunitybios-anktiva-plus-bcg-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-carcinoma-in-situ/"
X Link 2025-07-08T02:01Z 16.5K followers, [----] engagements
"Our scientists are working to develop remarkable new therapies that harness the body's inherent power by amplifying both the innate and adaptive branches of the immune system facilitating the attack and elimination of cancerous or infected cells today while building immunological memory for tomorrow. Learn more: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-07-10T14:35Z 16.5K followers, [----] engagements
"According to the American Cancer Society lung cancer accounts for nearly [--] in [--] cancer deaths in the United States. ImmunityBio is focused on developing therapies that address this ongoing health challenge. Read more: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2025-07-15T14:28Z 16.5K followers, [----] engagements
"Our scientists translate rigorous immunology research into innovative cell- and immune-based therapies working every day to expand treatment options and improve outcomes for patients"
X Link 2025-07-21T16:30Z 16.5K followers, [----] engagements
"Weve reported a 60% revenue increase in Q2 [----] with year-to-date sales reaching $43M and a 246% growth in ANKTIVA sales since J-code issuance. Regulatory milestones continue to help us advance our mission of improving outcomes for patients. Read more: https://immunitybio.com/immunitybio-reports-60-increase-in-revenue-in-q2-2025-with-year-to-date-sales-of-43-million-and-246-unit-growth-since-j-code-with-regulatory-updates/ https://immunitybio.com/immunitybio-reports-60-increase-in-revenue-in-q2-2025-with-year-to-date-sales-of-43-million-and-246-unit-growth-since-j-code-with-regulatory-updates/"
X Link 2025-07-25T16:16Z 16.5K followers, [----] engagements
"Lymphopenia remains a critical challenge for patients undergoing cancer treatment often compromising immune function and increasing the risk of complications. At ImmunityBio we are advancing clinical research aimed at promoting immune system recover and improving long-term outcomes for patients. Learn more: https://immunitybio.com/lymphopenia/ https://immunitybio.com/lymphopenia/"
X Link 2025-07-29T19:39Z 16.5K followers, [----] engagements
"Last night on Killing Cancer our Founder and Executive Chairman @DrPatSoonShiong joined @ChrisCuomo to discuss why re-examining long-held assumptions about cancer is essential to advancing patients treatment options. The special underscores his decades-long commitment to pursuing better ways to treat cancer and improve outcomes work that ImmunityBio continues to drive forward every day. https://www.newsnationnow.com/health/newsnation-special-killing-cancer-treatment-soon-shiong/ https://www.newsnationnow.com/health/newsnation-special-killing-cancer-treatment-soon-shiong/"
X Link 2025-11-26T14:26Z 15.5K followers, [----] engagements
"Our founder and Executive Chairman Dr. Patrick Soon-Shiong had the honor of carrying the Olympic torch in Athens at the historic stadium - representing Los Angeles and the United States as the flame was passed to Italy for the [----] Games"
X Link 2025-12-05T15:41Z 13.2K followers, [---] engagements
"We've announced the Announce Inaugural U.S.-Saudi Biotech Alliance Summit which will bring together national leaders from the United States and the Kingdom of Saudi Arabia across government healthcare delivery biotechnology advanced manufacturing artificial intelligence and finance. The Summit is designed to foster implementation and collaboration to accelerate the development manufacturing and global deployment of next-generation immunotherapies and healthcare technologies. Learn more:"
X Link 2026-01-12T15:00Z 13.8K followers, [----] engagements
"Her Royal Highness Princess Dr. Haya Al Saud joined ImmunityBios Founder Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong for a discussion on the future of human health and resilience. As a leader of the Hevolution Foundation Princess Haya Al Saud shared a powerful vision for longevity science: emphasizing the importance of strengthening biology and expanding how progress is measured. My dream would be to make healthspan a measure of GDP. https://twitter.com/i/web/status/2011512082588631521 https://twitter.com/i/web/status/2011512082588631521"
X Link 2026-01-14T18:53Z 16.5K followers, 77.8K engagements
"Progress isn't measured only in milestones but in its impact on people. At ImmunityBio our work is centered on translating scientific innovation into outcomes that matter. Explore what's next in our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2026-02-09T16:31Z 16.5K followers, [----] engagements
"Glioblastoma presents significant scientific and clinical challenges for patients and healthcare providers. The disease's limited treatment options emphasize the need for continued research and deeper scientific understanding. Our efforts in the glioblastoma space are focused on advancing studies designed to better comprehend the cancer and explore innovative therapeutic approaches. Learn more about ImmunityBio's glioblastoma clinical trial: https://immunitybio.com/glioblastoma/ https://immunitybio.com/glioblastoma/"
X Link 2026-02-12T15:20Z 16.5K followers, 21.7K engagements
"We believe our science has the potential to change the current paradigm of care for patients. Through a combination of highly experienced and talented people deep scientific knowledge and advanced research and manufacturing facilities ImmunityBio aims to improve outcomes for those living with difficult-to-treat diseases. Learn more about our founder's vision: https://immunitybio.com/founders-vision/ https://immunitybio.com/founders-vision/"
X Link 2025-08-04T18:00Z 16.5K followers, [----] engagements
"Bladder cancer incidence is rising but so are the options for patients facing this diagnosis. At ImmunityBio we are working to improve outcomes and reduce the burden of treatment for patients with non-muscle invasive bladder cancer. As the need grows so does our commitment to developing solutions designed to harness the body's own immune system. https://twitter.com/i/web/status/1953111107784327668 https://twitter.com/i/web/status/1953111107784327668"
X Link 2025-08-06T15:09Z 16.5K followers, [----] engagements
"Veterans are at an increased risk for bladder cancer due to exposure to carcinogens during service. Houston's Michael E. DeBakey VA Medical Center is now among the first VA hospitals to offer ANKTIVA for eligible veterans with BCG-unresponsive NMIBC. Read more: https://immunitybio.com/immunitybio-announces-houstons-michael-e-debakey-va-medical-center-is-among-the-first-va-hospitals-to-administer-anktiva-to-bladder-cancer-patients/"
X Link 2025-08-11T14:16Z 16.5K followers, [----] engagements
"Our robust pipeline of clinical trials is all about turning insights into better outcomes for people facing a wide range of cancers. The ImmunityBio team remains committed to transforming research into tangible impact in the lives of patients. Explore our latest trials: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-08-12T15:56Z 16.5K followers, [----] engagements
"We announced early results from our QUILT-106 Phase I trial showing complete responses in the first two late-stage Non-Hodgkin Waldenstrm lymphoma patients treated with our CD19 CAR-NK cell therapy. Learn more: https://immunitybio.com/immunitybio-reports-complete-responses-in-non-hodgkin-waldenstrom-lymphoma-patients-with-chemotherapy-free-first-in-class-cd19-car-nk-immunotherapy/ https://immunitybio.com/immunitybio-reports-complete-responses-in-non-hodgkin-waldenstrom-lymphoma-patients-with-chemotherapy-free-first-in-class-cd19-car-nk-immunotherapy/"
X Link 2025-08-13T13:14Z 16.5K followers, 96.5K engagements
"We're focused on innovating beyond standard treatments so that we can give the body the tools it needs to lead its own fight against cancer. Learn more about our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-09-02T14:25Z 16.5K followers, [----] engagements
"September marks Ovarian Cancer Awareness Month; a time to highlight the importance of early detection and ongoing research in the fight against this disease. Our team is always striving to push the boundaries of what is possible in ovarian cancer treatment. This month and every month we're dedicated to supporting patients and driving research forward. Learn more about our trial: https://immunitybio.com/ovarian-cancer/ https://immunitybio.com/ovarian-cancer/"
X Link 2025-09-03T20:20Z 16.5K followers, [----] engagements
"With high rates of recurrence and the risk of advancing disease non-muscle invasive bladder cancer (NMIBC) remains a significant burden for both patients and healthcare providers. ImmunityBio is working to meet this challenge through the development of innovative treatment approached aimed at addressing the disease more effectively. Learn more: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2025-09-16T15:54Z 16.4K followers, [----] engagements
"Lung cancer remains one of the leading causes of cancer-related deaths worldwide. At ImmunityBio we are advancing clinical research to explore new treatment options that harness the immune system. Our goal is to help expand possibilities for patients facing this disease. Learn more about our research: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2025-09-24T18:37Z 16.4K followers, [----] engagements
"ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patients immune system not weakening it. View our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-10-06T15:45Z 16.4K followers, [----] engagements
"Addressing the complexities of cancer and infectious diseases fuels our pursuit of new therapies that provide better outcomes for patients. If you're looking for a career with purpose become a part of our innovative team: https://immunitybio.com/careers/ https://immunitybio.com/careers/"
X Link 2025-10-14T14:40Z 16.5K followers, [----] engagements
"This weekend's BCAN Patient Summit in Columbus brought together patients caregivers and healthcare professionals united in their commitment to improving outcomes and quality of life for those affected by bladder cancer. We're proud to stand alongside @BladderCancerUS and the broader advocacy community in this mission. https://twitter.com/i/web/status/1980289869403533722 https://twitter.com/i/web/status/1980289869403533722"
X Link 2025-10-20T15:07Z 16.5K followers, [----] engagements
"At ImmunityBio we're dedicated to pushing the boundaries of medical research. By participating in our clinical trials individuals help us innovate and shape the future of cancer and infectious disease treatment. Learn more: https://immunitybio.com/find-a-trial/ https://immunitybio.com/find-a-trial/"
X Link 2025-10-27T15:22Z 16.4K followers, [----] engagements
"This National Urology Nurses Week ImmunityBio recognizes the dedication and expertise of urology nurses who provide compassionate care to patients every day. Your commitment helps improve outcomes and quality of life for individuals navigating urologic conditions including bladder cancer. Thank you for all that you do. https://twitter.com/i/web/status/1985360359205794185 https://twitter.com/i/web/status/1985360359205794185"
X Link 2025-11-03T14:56Z 16.5K followers, [----] engagements
"Bladder Health Month provides us with an opportunity to reflect on the progress made through science and the compassion that drives it forward. Behind every clinical advancement are patients nurses physicians and caretakers determined to improve the future of bladder cancer care. We share that mission - to transform how bladder cancer is treated and to restore the body's ability to fight disease. Together with organizations like @BladderCancerUS and @UrologyCareFdn we work toward a future defined by better outcomes and renewed hope. https://twitter.com/i/web/status/1986084840928924003"
X Link 2025-11-05T14:55Z 16.5K followers, [----] engagements
"We reported another quarter of strong results driven by increased demand for ANKTIVA and continued progress across our immunotherapy pipeline. In Q3 [----] we achieved significant year-to-date unit growth of 467% and $75 million in total product sales reflecting growing adoption in BCG-unresponsive non-muscle invasive bladder cancer. As we close out the year we remain committed to expanding access to our therapies advancing ongoing trials across multiple indications and executing our long-term vision to transform how cancer is treated. Read the full release including important cautionary"
X Link 2025-11-06T18:23Z 16.5K followers, [----] engagements
"Every November Lung Cancer Awareness Month shines a light on the importance of education early detection and innovation. ImmunityBio is proud to support this awareness by pursuing scientific advancements designed to improve outcomes for patients facing lung cancer. Learn more: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2025-11-07T14:58Z 16.5K followers, [----] engagements
"Hope moves science forward. This month we honor the strength of the bladder cancer community and remain committed to transforming the treatment landscape through therapies that empower the immune system to fight cancer more effectively"
X Link 2025-11-10T15:34Z 16.5K followers, [----] engagements
"This Veterans Day we reflect on the sacrifices made by those who served our country and the importance of improving health outcomes for veterans living with cancer and other serious diseases. Their resilience drives our ongoing pursuit of better care for all patients. Thank you. https://twitter.com/i/web/status/1988256773657292939 https://twitter.com/i/web/status/1988256773657292939"
X Link 2025-11-11T14:45Z 16.5K followers, [----] engagements
"A recent Harris survey found that a vast majority of patients with non-muscle invasive bladder cancer (NMIBC) see intravesical chemotherapy as a last resort whereas 72% of immunotherapy recipients are satisfied with the duration of positive treatment effects. With patients at the forefront ImmunityBio continues to focus on innovative approaches designed to preserve bladder function and improve quality of life for those facing difficult treatment decisions. Read more here: https://immunitybio.com/new-survey-reveals-non-muscle-invasive-bladder-cancer-patients-seek-more-care-conversations/"
X Link 2025-11-13T14:14Z 16.4K followers, [----] engagements
"During our National Sales Meeting we came together to align on our vision for the year ahead; one rooted in innovation collaboration and meaningful impact. From inspiring presentations to strategy sessions every moment reinforced our dedication to driving progress for patients. We leave this meeting energized and focused on the work matters most - making a lasting difference in cancer care. https://twitter.com/i/web/status/1989382511408156911 https://twitter.com/i/web/status/1989382511408156911"
X Link 2025-11-14T17:18Z 16.4K followers, [----] engagements
"Lung Cancer Awareness Month is a time to recognize the progress made and the work still ahead. Non-small cell lung cancer (NSCLC) accounts for over 85% of all lung cancer cases in the U.S. with more than [------] diagnoses each year. Our work focuses on developing immunotherapy treatments that strengthen the body's natural immune response to target and destroy cancer cells. Through clinical research and collaboration we aim to deliver treatments that extend survival and improve quality of life for those affected. Learn more about our NSCLC clinical trial:"
X Link 2025-11-17T16:59Z 16.4K followers, [----] engagements
"We're honored to collaborate with the Saudi leadership team as we work to advance research and identify opportunities to reach more patients in need"
X Link 2025-11-20T16:49Z 16.4K followers, 12.9K engagements
"Our Founder and Executive Chairman Dr. Patrick Soon-Shiong recently sat down with @ChrisCuomo to share insights on the evolving landscape of cancer research and scientific innovation. Watch Killing Cancer Tuesday November [--] at 10p/9C on NewsNation"
X Link 2025-11-20T20:10Z 16.4K followers, [----] engagements
"The [----] National Health Interview Survey shows a powerful truth: if lung cancer screenings were to reach 100% [-----] lives could be saved in a mere five years. As we recognize Lung Cancer Awareness Month insights like this reinforce why ImmunityBio is investing in new approaches that aim to expand treatment options and address the challenges in lung cancer care. https://twitter.com/i/web/status/1991937478379626553 https://twitter.com/i/web/status/1991937478379626553"
X Link 2025-11-21T18:31Z 16.4K followers, [----] engagements
"As we reflect on this past year were reminded of the many things we hold with gratitude - our dedicated team the physicians and caregivers who make exceptional care possible and the patients whose resilience inspires every step forward. Together were continuing to advance science in the pursuit of better outcomes for those facing cancer. https://twitter.com/i/web/status/1994178833239691757 https://twitter.com/i/web/status/1994178833239691757"
X Link 2025-11-27T22:57Z 16.4K followers, [----] engagements
"While the exact cause of glioblastoma remains unknown several risk factors have been linked to increased risk - including age gender prior exposure to radiation and rare genetic conditions. For many patients however glioblastoma develops without a clear identifiable cause. At ImmunityBio we're conducting clinical research to better understand glioblastoma and evaluate investigational therapies that may offer new options for patients facing this difficult diagnosis. To learn more about our research visit https://immunitybio.com/glioblastoma/ https://immunitybio.com/glioblastoma/"
X Link 2025-12-01T17:57Z 16.4K followers, [----] engagements
"We look forward to participating in the Society of Urologic Oncology's 26th Annual Meeting. Opportunities for collaboration at these meetings are essential in advancing new breakthroughs in bladder cancer care and we're committed to contributing to ongoing innovation in the space. @UroOnc https://twitter.com/i/web/status/1995955710400791008 https://twitter.com/i/web/status/1995955710400791008"
X Link 2025-12-02T20:38Z 16.4K followers, [----] engagements
"Our Founder and Executive Chairman Dr. Patrick Soon-Shiong had the honor of carrying the Olympic torch in Athens at the historic stadium - representing Los Angeles and the United States as the flame was passed to Italy for the [----] Games"
X Link 2025-12-05T15:42Z 16.4K followers, [----] engagements
"Patient voices matter. According to a new Harris survey 72% of patients with non-muscle invasive bladder cancer express a preference to keep chemotherapy as a later option in their treatment plan instead of a first-line approach. At ImmunityBio we're working to develop patient-focused approaches that help the immune system target cancer cells. Read more: https://immunitybio.com/new-survey-reveals-non-muscle-invasive-bladder-cancer-patients-seek-more-care-conversations/ https://immunitybio.com/new-survey-reveals-non-muscle-invasive-bladder-cancer-patients-seek-more-care-conversations/"
X Link 2025-12-09T15:08Z 16.4K followers, [----] engagements
"Non-muscle invasive bladder cancer is challenging due to its tendency to recur often bringing financial strain and reduced quality of life for patients. At ImmunityBio we're dedicated to bringing forward new therapies that offer meaningful hope to those navigating this condition. Learn more about our efforts in the bladder cancer space: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2025-12-11T18:04Z 16.4K followers, [----] engagements
"Lymphopenia can be a significant concern for patients with cancer as both chemotherapy and radiation can markedly lower lymphocyte levels. Reduced immune cell counts may affect how patients tolerate treatment and respond to infections. Learn more about how we're working to address lymphopenia for better patient outcomes: https://immunitybio.com/lymphopenia/ https://immunitybio.com/lymphopenia/"
X Link 2025-12-15T14:57Z 16.4K followers, [----] engagements
"New data from our Phase 2/3 study shows that ANKTIVA (nogapendekin alfa inbakicept) plus BCG demonstrated a 96% overall survival rate at three years in patients with BCG-unresponsive high-grade papillary-only non-muscle invasive bladder cancer (NMIBC). These findings add to the clinical significance of immunotherapy's role in bladder cancer a space where treatment options have historically been limited. Read more:"
X Link 2025-12-16T15:04Z 16.4K followers, 10.4K engagements
"As we reflect on the year behind us we're grateful for the progress made through science collaboration and shared purpose. Without the patients caregivers healthcare heroes researchers and our amazing team this year's progress would not have been possible. At ImmunityBio our work continues with a clear focus: advancing therapies that support better patient outcomes. We wish you health and peace this holiday season. https://twitter.com/i/web/status/2004218295092686957 https://twitter.com/i/web/status/2004218295092686957"
X Link 2025-12-25T15:50Z 16.4K followers, [----] engagements
"ImmunityBio's Founder Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong has been recognized by @oncodaily as one of The [---] Most Influential People in Oncology in [----]. Dr. Soon-Shiong has earned this honor in recognition of his lifelong commitment to science medicine and patient care a commitment that inspires our team and our partners every day said Richard Adcock President and CEO of ImmunityBio. His ideas and leadership are a driving force powering our mission to bring transformative therapies to people living with cancer and other serious"
X Link 2025-12-29T14:07Z 16.4K followers, [----] engagements
"As we reflect on [----] we recognize a year shaped by collaboration scientific progress and meaningful engagement across the healthcare community. From connecting with patients and their caregivers to working cross-functionally as a means of moving initiatives forward each effort contributed to strengthening our mission and vision. Looking ahead to [----] we remain focused on building on this momentum; continuing to advance our science and support important communities with purpose and intention. Learn more about our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2026-01-01T19:07Z 16.4K followers, [----] engagements
"Firefighters face a higher risk of bladder cancer and other cancers due to repeated exposure to carcinogens in the line of duty. While they dedicate their lives to protecting others their own health is often put at risk in the process. During Firefighter Cancer Awareness Month ImmunityBio remains focused on supporting efforts that increase awareness of cancer risk promote informed conversations between patients and healthcare providers and advance research aimed at improving outcomes for those affected by non-muscle invasive bladder cancer. https://twitter.com/i/web/status/2007102939631136897"
X Link 2026-01-02T14:53Z 16.4K followers, [----] engagements
"In [----] the International Agency for Research on Cancer (IARC) classified firefighting as a Class [--] carcinogenic occupation the highest level of evidence linking an exposure to cancer in humans. This designation reflects consistent documentation that firefighters encounter carcinogens through multiple pathways including: inhalation of toxic smoke dermal absorption of chemicals and contaminated turnout gear and equipment. These exposure have been associated with an increased risk of several cancers including bladder cancer. Understanding these exposure pathways is essential to advancing"
X Link 2026-01-06T14:43Z 16.4K followers, [----] engagements
"You can help shape the future of cancer treatment by joining the ImmunityBio team. We're hiring passionate individuals committed to advancing research and developing innovative therapies that improve patient outcomes. Start your journey with us: https://immunitybio.com/careers/ https://immunitybio.com/careers/"
X Link 2026-01-09T16:16Z 16.4K followers, [----] engagements
"We've announced the Inaugural U.S.-Saudi Biotech Alliance Summit which will bring together national leaders from the United States and the Kingdom of Saudi Arabia across government healthcare delivery biotechnology advanced manufacturing artificial intelligence and finance. The Summit is designed to foster implementation and collaboration to accelerate the development manufacturing and global deployment of next-generation immunotherapies and healthcare technologies. Learn more:"
X Link 2026-01-12T18:36Z 16.4K followers, [----] engagements
"Were continuing to advance our first-line BCG-nave non-muscle invasive bladder cancer program with enrollment exceeding expectations in our randomized registrational trial evaluating ANKTIVA plus BCG. These early milestones underscore our continued focus on moving this program forward and addressing unmet needs in bladder cancer. Read more: https://immunitybio.com/immunitybio-advances-first-line-bcg-naive-nmibc-program-with-enrollment-exceeding-expectations-and-positive-interim-analysis-for-anktiva-plus-bcg/"
X Link 2026-01-16T15:33Z 16.4K followers, 10.1K engagements
"Cancer is a leading cause of death among firefighters accounting for approximately 66% of firefighter line-of-duty deaths according to the Firefighter Cancer Support Network. These exposures have been linked to elevated cancer risk across multiple sites including bladder cancer. Our work is informed by the realities of occupational cancer risk and underscores the importance of continued research that focuses on improving outcomes for affected patients. Learn more about our efforts in the bladder cancer space: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2026-01-19T17:38Z 16.4K followers, [----] engagements
"We've announced our new study called COVID-4.019-Long which further expands our clinical research efforts to assess ANKTIVAs potential beyond cancer or cancer-related diseases. Learn more about the study and its potential impact: https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-phase-2-study-anktivar-patients-long-covidfield_nir_news_date_valuemin= https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-phase-2-study-anktivar-patients-long-covidfield_nir_news_date_valuemin="
X Link 2025-08-19T12:45Z 16.4K followers, 19.2K engagements
"Weve announced that our initial data shows 100% disease control in [--] out of [--] patients with recurrent glioblastoma after being treated with our ANKTIVA NK cell therapy plus the Optune Gio device. Read more: https://immunitybio.com/initial-data-shows100-disease-control-in-5-out-of-5-patients-with-recurrent-glioblastoma-with-two-patients-in-near-complete-response-treated-with-immunitybios-anktiva-nk-cell-therapy-p/"
X Link 2025-08-26T12:46Z 16.5K followers, 37.6K engagements
"Weve announced new paradigm-changing findings from the Phase [--] QUILT-3.055 study demonstrating ANKTIVA (nogapendekin alfa inbakicept-pmln) reverses lymphopenia (low natural killer and T cells) in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer (NSCLC) with this reversal resulting in significant prolonged median overall survival (mOS). Read more: https://immunitybio.com/immunitybios-anktiva-reverses-lymphopenia-and-extends-overall-survival-in-patients-with-advanced-non-small-cell-lung-cancer-resistant-to-checkpoint-therapy/"
X Link 2025-09-08T13:25Z 16.5K followers, 13.3K engagements
"ANKTIVA plus BCG has received a positive recommendation for marketing authorization in the EU for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) with or without papillary tumors. The recommendation reflects the EMAs determination that earlier patient access is warranted and represents an important step forward for individuals with BCG-unresponsive disease an area with otherwise limited treatment options. Learn more:"
X Link 2025-12-12T12:15Z 16.4K followers, 59.4K engagements
"The European Medicines Agency has granted conditional marketing authorization for ANKTIVA + BCG for patients with BCG-unresponsive NMIBC CIS in the European Union. This gives eligible patients in the EU access to our innovative treatment. Once the European Commission (EC) gives its final approval it will broadly expand the reach of ANKTIVA from two to [--] nations including the U.K. and U.S. Learn more:"
X Link 2025-12-19T16:51Z 16.4K followers, [----] engagements
"New data demonstrates that ANKTIVA enhances immune restoration when combined with checkpoint inhibitors in NSCLC with statistically significant increases in absolute lymphocyte counts and corresponding survival benefits that reinforce its role as a promising lymphocyte-stimulating agent. Read more: https://immunitybio.com/immunitybio-announces-positive-results-demonstrating-anktiva-as-a-lymphocyte-stimulating-agent-in-combination-with-checkpoint-inhibitors-in-non-small-cell-lung-cancer/"
X Link 2026-01-13T15:03Z 16.4K followers, 59.7K engagements
"Today the Saudi Food and Drug Authority (SFDA) granted accelerated approval of ANKTIVA for use in combination with immune checkpoint inhibitors for adult patients with metastatic NSCLC whose disease has progressed following standard-of-care therapy. This marks the first approval anywhere in the world for ANKTIVA in this indication. Learn more: https://immunitybio.com/saudi-fda-grants-accelerated-approval-to-immunitybios-anktiva-in-combination-with-checkpoint-inhibitors-for-metastatic-non-small-cell-lung-cancer/"
X Link 2026-01-14T15:30Z 16.4K followers, 14.3K engagements
"At ImmunityBio we reported approximately $113 million in preliminary net product revenue for [----] representing a 700% year-over-year increase. This continued momentum reflects steady execution and growing adoption of ANKTIVA - and most importantly progress toward our mission to advance therapies designed to restore the bodys natural ability to fight cancer. Read more: https://immunitybio.com/immunitybio-reports-continued-execution-and-sales-momentum-with-113-million-of-preliminary-net-product-revenue-a-700-increase-year-over-year/"
X Link 2026-01-15T15:28Z 16.4K followers, 14.5K engagements
"Dr. Patrick Soon-Shiong ImmunityBio's Founder Executive Chairman and Global Chief Scientific and Medical Officer also met with His Excellency Dr Bandar Alknawy to discuss the role of King Abdullah International Medical Research Center (KAIMRC) in advancing Saudi Arabias National Biotechnology Strategy. Their conversation highlighted how KAIMRC is contributing to scientific innovation health resilience and long-term economic growth key pillars of Vision [----]. Together these efforts reflect a shared commitment to strengthening international research capabilities and positioning biotechnology as"
X Link 2026-01-15T20:13Z 16.4K followers, 33.8K engagements
"ImmunityBio reported that median overall survival has not yet been reached in patients with recurrent or progressive glioblastoma treated with a chemo-free ANKTIVA + CAR-NK-based regimen. As recent @AmericanCancer data shows that brain cancer is now the third leading cause of cancer-related death among adults ages [----] these findings underscore the urgency of continued innovation in this disease. Read more: https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-reports-median-overall-survival-not-yet-reached-andfield_nir_news_date_value%5Bmin%5D="
X Link 2026-01-23T12:19Z 16.4K followers, 105.9K engagements
"Firefighters face danger every day both visible and unseen. Research has shown that firefighters are at an increased risk for certain cancers including bladder cancer making awareness and timely diagnosis critical. Our advancements in bladder cancer are guided by a mission to improve outcomes and expand treatment possibilities. Learn more about what ImmunityBio is doing in the bladder cancer space: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2026-01-26T15:32Z 16.4K followers, [----] engagements
"At this weeks MAHA Media Hub Dr. Patrick Soon-Shiong Founder Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio shared insights on the evolving understanding of cancer and why advancing beyond traditional treatment paradigms is essential. His perspective underscored the importance of rethinking how we approach cancer with a focus on science-driven innovation and the bodys own immune system as a critical part of the solution. Watch now: https://immunitybio.com/maha-action-media-hub/ https://immunitybio.com/maha-action-media-hub/"
X Link 2026-01-30T16:52Z 16.4K followers, 18.4K engagements
"World Cancer Day serves as a reminder of the determination resilience and strength behind every cancer patient's journey - and the importance of continued progress in care. Our work is driven by the responsibility to move cancer research forward to deliver meaningful outcomes and help shape a more hopeful future for patients. https://twitter.com/i/web/status/2019082540792127800 https://twitter.com/i/web/status/2019082540792127800"
X Link 2026-02-04T16:16Z 16.4K followers, [----] engagements
"Progress in non-muscle invasive bladder cancer (NMIBC) depends on continued innovation in how the disease is treated and managed over time. As patients and healthcare providers navigate complex care decisions ImmunityBio is advancing new therapeutic approaches designed to support improved outcomes. Learn more: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2026-01-20T18:36Z 16.5K followers, 11K engagements
"At ImmunityBio our pipeline continues to expand with chemotherapy-free approaches designed to harness the power of one's own immune system. We have launched ResQ215B a Phase [--] clinical study evaluating a novel chemotherapy-free and lymphodepletion-free combination immunotherapy in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) including Waldenstrms Macroglobulinemia. Learn more: https://immunitybio.com/immunitybio-launches-phase-2-chemotherapy-free-car-nk-cell-therapy-trial-with-anktiva%ef%83%92-resq215b-in-indolent-lymphomas/"
X Link 2026-02-02T15:15Z 16.5K followers, 61.3K engagements
"ImmunityBio Founder Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong recently joined the @OncBrothers podcast to explore the science and patient impact behind what it takes to be a true game-changer in oncology. This wasnt just a discussion about a drug but a conversation about rebuilding the immune system and rethinking what the future of cancer care must look like. Listen in and hear how ImmunityBio is pushing immunotherapy forward starting with the immune system itself: https://www.youtube.com/watchv=aRDyqswYUOY&t=4s"
X Link 2026-02-09T20:13Z 16.5K followers, 94.8K engagements
"As a company that believes medicine should not only treat but transform lives we pursue outcomes that matter. Our team is deeply connected to this mission many of us driven by personal experiences that fuel our commitment. In every breakthrough there is a shared drive to make a difference - because for us this work is personal. https://twitter.com/i/web/status/2022395824358257024 https://twitter.com/i/web/status/2022395824358257024"
X Link 2026-02-13T19:41Z 16.5K followers, [----] engagements
"Weve announced that our initial data shows 100% disease control in [--] out of [--] patients with recurrent glioblastoma after being treated with our ANKTIVA NK cell therapy plus the Optune Gio device. Read more: https://immunitybio.com/initial-data-shows100-disease-control-in-5-out-of-5-patients-with-recurrent-glioblastoma-with-two-patients-in-near-complete-response-treated-with-immunitybios-anktiva-nk-cell-therapy-p/"
X Link 2025-08-26T12:46Z 16.5K followers, 37.6K engagements
"Thrilled about the news that our partners Drs. Hotez and Bottazzi have been nominated for the Nobel Prize for their work on low-cost #COVID-19 vaccine thats already in use in India. Congratulations on the well-deserved recognition @TexasChildrens @PeterHotez @mebottazzi"
X Link 2022-02-16T22:24Z 16.5K followers, [---] engagements
"The team at ImmunityBio extends our congratulations to Dr. Mary E. Brunkow Dr. Fred Ramsdell and Dr. Shimon Sakaguchi recipients of the [----] Nobel Prize in Physiology or Medicine. This groundbreaking research on regulatory T cells has advanced the scientific understanding of immune tolerance providing the foundation for developing novel therapies targeting cancer and infectious diseases. We recognize and applaud their contributions to immunology which continue to inspire innovation. Read more: https://www.nobelprize.org/prizes/medicine/2025/press-release/"
X Link 2025-10-08T14:37Z 16.5K followers, [----] engagements
"We've announced our new study called COVID-4.019-Long which further expands our clinical research efforts to assess ANKTIVAs potential beyond cancer or cancer-related diseases. Learn more about the study and its potential impact: https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-phase-2-study-anktivar-patients-long-covidfield_nir_news_date_valuemin= https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-phase-2-study-anktivar-patients-long-covidfield_nir_news_date_valuemin="
X Link 2025-08-19T12:45Z 16.4K followers, 19.2K engagements
"We announced early results from our QUILT-106 Phase I trial showing complete responses in the first two late-stage Non-Hodgkin Waldenstrm lymphoma patients treated with our CD19 CAR-NK cell therapy. Learn more: https://immunitybio.com/immunitybio-reports-complete-responses-in-non-hodgkin-waldenstrom-lymphoma-patients-with-chemotherapy-free-first-in-class-cd19-car-nk-immunotherapy/ https://immunitybio.com/immunitybio-reports-complete-responses-in-non-hodgkin-waldenstrom-lymphoma-patients-with-chemotherapy-free-first-in-class-cd19-car-nk-immunotherapy/"
X Link 2025-08-13T13:14Z 16.5K followers, 96.5K engagements
"We've announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the use of our Cancer BioShield platform anchored by ANKTIVA to treat lymphopenia in adult patients with refractory or relapsed solid tumors who have progressed after first-line standard-of-care treatment chemotherapy radiation or immunotherapy. Learn more: https://immunitybio.com/immunitybio-receives-fda-expanded-access-authorization-for-landmark-treatment-of-lymphopenia-with-anktiva-the-cancer-bioshield-platform-in-patients-with-solid-tumors/"
X Link 2025-06-02T14:10Z 16.5K followers, 10.2K engagements
"Weve announced new paradigm-changing findings from the Phase [--] QUILT-3.055 study demonstrating ANKTIVA (nogapendekin alfa inbakicept-pmln) reverses lymphopenia (low natural killer and T cells) in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer (NSCLC) with this reversal resulting in significant prolonged median overall survival (mOS). Read more: https://immunitybio.com/immunitybios-anktiva-reverses-lymphopenia-and-extends-overall-survival-in-patients-with-advanced-non-small-cell-lung-cancer-resistant-to-checkpoint-therapy/"
X Link 2025-09-08T13:25Z 16.5K followers, 13.3K engagements
"At ImmunityBio we're redefining cancer care. Our mission focuses on developing treatments that are not only effective but also aim to enhance patient comfort. Our team works to improve the experiences of those undergoing cancer treatment offering hope through innovative therapies. Learn more about our vision: https://immunitybio.com/founders-vision/ https://immunitybio.com/founders-vision/"
X Link 2025-06-03T14:02Z 16.5K followers, [----] engagements
"Today we announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted the first marketing approval outside the United States for this novel lymphocyte-stimulating agent ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Gurin (BCG) for the treatment of certain bladder cancer patients. Learn more: https://immunitybio.com/uk-mhra-approves-immunitybios-anktiva-plus-bcg-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-carcinoma-in-situ/"
X Link 2025-07-08T02:01Z 16.5K followers, [----] engagements
"Our scientists are working to develop remarkable new therapies that harness the body's inherent power by amplifying both the innate and adaptive branches of the immune system facilitating the attack and elimination of cancerous or infected cells today while building immunological memory for tomorrow. Learn more: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-07-10T14:35Z 16.5K followers, [----] engagements
"Weve reported a 60% revenue increase in Q2 [----] with year-to-date sales reaching $43M and a 246% growth in ANKTIVA sales since J-code issuance. Regulatory milestones continue to help us advance our mission of improving outcomes for patients. Read more: https://immunitybio.com/immunitybio-reports-60-increase-in-revenue-in-q2-2025-with-year-to-date-sales-of-43-million-and-246-unit-growth-since-j-code-with-regulatory-updates/ https://immunitybio.com/immunitybio-reports-60-increase-in-revenue-in-q2-2025-with-year-to-date-sales-of-43-million-and-246-unit-growth-since-j-code-with-regulatory-updates/"
X Link 2025-07-25T16:16Z 16.5K followers, [----] engagements
"Dr. Patrick Soon-Shiong presented groundbreaking insights on harnessing NK cells and memory T cells to fight urological cancers today at the #AUA2025 Innovation Nexus. Were honored to collaborate with healthcare professionals in advancing treatments for bladder cancer"
X Link 2025-04-25T20:29Z 16.5K followers, [----] engagements
"ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patients immune system not weakening it. View our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-10-06T15:45Z 16.4K followers, [----] engagements
"We announced the signing of a strategic Memorandum of Understanding (MOU) to introduce the FDA-approved Cancer BioShield platform to Saudi Arabia and the broader Middle East. Learn more: https://immunitybio.com/immunitybio-saudi-arabias-ministry-of-investment-kfshrc-and-kaimrc-sign-strategic-memorandum-of-understanding-to-launch-cancer-bioshieldtm-platform-in-the-middle-east/ https://immunitybio.com/immunitybio-saudi-arabias-ministry-of-investment-kfshrc-and-kaimrc-sign-strategic-memorandum-of-understanding-to-launch-cancer-bioshieldtm-platform-in-the-middle-east/"
X Link 2025-05-27T14:07Z 16.5K followers, 10.6K engagements
"Lymphopenia is a serious condition affecting many patients with cancer - especially those undergoing chemotherapy or radiation. It can leave the immune system compromised and limit the body's ability to fight illness. We're working to address this challenge through our science and ongoing clinical research with a goal of improving outcomes by enhancing immune recovery. https://twitter.com/i/web/status/1937512789037449583 https://twitter.com/i/web/status/1937512789037449583"
X Link 2025-06-24T14:07Z 16.5K followers, [----] engagements
"This weekend's BCAN Patient Summit in Columbus brought together patients caregivers and healthcare professionals united in their commitment to improving outcomes and quality of life for those affected by bladder cancer. We're proud to stand alongside @BladderCancerUS and the broader advocacy community in this mission. https://twitter.com/i/web/status/1980289869403533722 https://twitter.com/i/web/status/1980289869403533722"
X Link 2025-10-20T15:07Z 16.5K followers, [----] engagements
"We reported another quarter of strong results driven by increased demand for ANKTIVA and continued progress across our immunotherapy pipeline. In Q3 [----] we achieved significant year-to-date unit growth of 467% and $75 million in total product sales reflecting growing adoption in BCG-unresponsive non-muscle invasive bladder cancer. As we close out the year we remain committed to expanding access to our therapies advancing ongoing trials across multiple indications and executing our long-term vision to transform how cancer is treated. Read the full release including important cautionary"
X Link 2025-11-06T18:23Z 16.5K followers, [----] engagements
"We believe our science has the potential to change the current paradigm of care for patients. Through a combination of highly experienced and talented people deep scientific knowledge and advanced research and manufacturing facilities ImmunityBio aims to improve outcomes for those living with difficult-to-treat diseases. Learn more about our founder's vision: https://immunitybio.com/founders-vision/ https://immunitybio.com/founders-vision/"
X Link 2025-08-04T18:00Z 16.5K followers, [----] engagements
"Annually over [------] people in the United States are diagnosed with lung cancer with the majority facing non-small cell lung cancer (NSCLC). We're working to enhance the activity of NK and T cells empowering the immune system to better combat NSCLC. Learn more about our approach: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2025-06-19T14:11Z 16.5K followers, [----] engagements
"Join us in transforming the future of cancer treatment. ImmunityBio is advancing innovative therapies that bring new hope to patients facing some of the most challenging cancers. We're looking for passionate mission-driven individuals to grow with us. Be a part of something bigger. Explore open positions and apply today: https://immunitybio.com/careers/ https://immunitybio.com/careers/"
X Link 2025-06-26T15:05Z 16.5K followers, [----] engagements
"Yesterdays investor meeting was an important moment to align with key opinion leaders and shareholders on our continued progress toward delivering better treatment options for patients"
X Link 2025-04-16T14:33Z 16.5K followers, [----] engagements
"Were thrilled to announce today @US_FDA approved a first-in-class treatment for BCG-unresponsive non-muscle invasive bladder cancer #NMIBC. Learn more: $IBRX https://immunitybio.com/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer/ https://immunitybio.com/immunitybio-announces-fda-approval-of-anktiva-first-in-class-il-15-receptor-agonist-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer/"
X Link 2024-04-23T02:12Z 16.5K followers, [----] engagements
"At ImmunityBio we're dedicated to pushing the boundaries of medical research. By participating in our clinical trials individuals help us innovate and shape the future of cancer and infectious disease treatment. Learn more: https://immunitybio.com/find-a-trial/ https://immunitybio.com/find-a-trial/"
X Link 2025-10-27T15:22Z 16.4K followers, [----] engagements
"Veterans are at an increased risk for bladder cancer due to exposure to carcinogens during service. Houston's Michael E. DeBakey VA Medical Center is now among the first VA hospitals to offer ANKTIVA for eligible veterans with BCG-unresponsive NMIBC. Read more: https://immunitybio.com/immunitybio-announces-houstons-michael-e-debakey-va-medical-center-is-among-the-first-va-hospitals-to-administer-anktiva-to-bladder-cancer-patients/"
X Link 2025-08-11T14:16Z 16.5K followers, [----] engagements
"The FDA has granted ImmunityBio a Regenerative Medicine Advanced Therapy designation to evaluate whether ANKTIVA and CAR-NK can reverse lymphopenia in patients undergoing standard-of-care chemotherapy for locally advanced or metastatic pancreatic cancer. Learn more about our innovative approach to addressing this unmet need in cancer: https://immunitybio.com/immunitybio-receives-fda-rmat-designation-for-anktiva-and-car-nk-for-the-reversal-of-lymphopenia-in-patients-receiving-standard-of-care-chemotherapy-radiotherapy-and-in-treatment-of-multiply-rel/"
X Link 2025-02-28T00:20Z 16.5K followers, [----] engagements
"On this International Clinical Trials Day we at ImmunityBio are dedicated to transforming the future of cancer treatment. This journey wouldn't be possible without the invaluable contributions of our clinical trial participants. Together we are pioneering breakthroughs"
X Link 2025-05-20T15:28Z 16.5K followers, [----] engagements
"We're focused on innovating beyond standard treatments so that we can give the body the tools it needs to lead its own fight against cancer. Learn more about our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-09-02T14:25Z 16.5K followers, [----] engagements
"Lymphopenia remains a critical challenge for patients undergoing cancer treatment often compromising immune function and increasing the risk of complications. At ImmunityBio we are advancing clinical research aimed at promoting immune system recover and improving long-term outcomes for patients. Learn more: https://immunitybio.com/lymphopenia/ https://immunitybio.com/lymphopenia/"
X Link 2025-07-29T19:39Z 16.5K followers, [----] engagements
"Our robust pipeline of clinical trials is all about turning insights into better outcomes for people facing a wide range of cancers. The ImmunityBio team remains committed to transforming research into tangible impact in the lives of patients. Explore our latest trials: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-08-12T15:56Z 16.5K followers, [----] engagements
"Join us now at the product theater where Dr. Patrick Soon-Shiong is presenting our innovative approach to addressing the BCG shortage in bladder cancer. Learn how were advancing therapeutics for better patient outcomes"
X Link 2025-04-27T20:40Z 16.5K followers, [----] engagements
"According to the American Cancer Society lung cancer accounts for nearly [--] in [--] cancer deaths in the United States. ImmunityBio is focused on developing therapies that address this ongoing health challenge. Read more: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2025-07-15T14:28Z 16.5K followers, [----] engagements
"Bladder cancer recurrence is a reality for nearly half of patients with non-muscle invasive disease. ImmunityBio is advancing immunotherapy-based research to help the body's own defenses recognize and fight cancer. Learn more: https://immunitybio.com/bladder-cancer/ https://immunitybio.com/bladder-cancer/"
X Link 2025-07-02T13:44Z 16.5K followers, [----] engagements
""Smart therapies for difficult diseases" isn't just a phrase - it is the foundation of everything we do. At ImmunityBio we're working to transform how cancer is treated by designing therapies that not only target disease but restore the body's natural ability to fight it. View our pipeline: https://immunitybio.com/pipeline/ https://immunitybio.com/pipeline/"
X Link 2025-06-16T14:43Z 16.5K followers, [----] engagements
"Lung cancer remains one of the leading causes of cancer-related deaths worldwide. At ImmunityBio we are advancing clinical research to explore new treatment options that harness the immune system. Our goal is to help expand possibilities for patients facing this disease. Learn more about our research: https://immunitybio.com/non-small-cell-lung-cancer/ https://immunitybio.com/non-small-cell-lung-cancer/"
X Link 2025-09-24T18:37Z 16.4K followers, [----] engagements
"Today we announced our first patient dosed in our recombinant BCG (rBCG) FDA-authorized Expanded Access Program. With [--] sites launching providers like U.S. Urology Partners are helping address the nationwide BCG shortage. Learn more: https://immunitybio.com/immunitybio-announces-first-dosing-of-recombinant-bcg-rbcg-in-the-u-s-and-60-sites-in-the-process-of-launching/ https://immunitybio.com/immunitybio-announces-first-dosing-of-recombinant-bcg-rbcg-in-the-u-s-and-60-sites-in-the-process-of-launching/"
X Link 2025-03-13T13:57Z 16.5K followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing